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Chondroitin Sulphate Proteoglycan-4 (CSPG4), also known as nerve/glial antigen 2 (NG2), 
High Molecular Weight-Melanoma Associated Antigen (HMW-MAA), or melanoma 
chondroitin sulfate proteoglycan (MCSP), is a cell surface proteoglycan with biological and 
clinical significance, which have been first characterized in a high-molecular-weight type 1 
membrane proteoglycan in rat in 19811, and then identified with mouse monoclonal 
antibody (mAb) on human melanoma cells2.  It is a chondroitin sulfate proteoglycan that 
consists of an N-linked glycoprotein of 280 kDa and a proteoglycan component of about 450 
kDa3,4,5 and plays an important role in cell proliferation, migration, and metastasis6. It is 
expressed on the surface of various types of immature progenitor cells and its expression 
decreases with terminal differentiation7,8. NG2/CSPG4 has been supposed to be  involved in 
platelet-derived growth factor (PDGF) signaling in oligodendrocyte precursor cells (OPCs)9, 
where its expression is widely used as a marker for these cells10. NG2/CSPG4 is mostly 
expressed by human malignant melanoma cells11, tumors of neuroectodermal origin12–15, on 
tumour neovasculature by vascular pericytes in human malignant brain tumours16, on basal 
breast carcinoma17, squamous carcinoma of the head and neck (SCCHN)18, pancreatic 
carcinoma, some types of renal cell carcinoma, chordoma11,19, chondrosarcoma cells19 and 
mesothelioma6,19. Moreover, NG2/CSPG4 is highly expressed in uveal melanomas20,21 and 
soft tissue sarcomas22 where enhanced expression levels of NG2/CSPG4 proteoglycan 
provides a molecular factor that alone prospects a particularly unfavorable clinical22,23 and 
mediates a poor prognosis in childhood acute myeloid leukaemia (AML) patients24. 
Aberrant expression of NG2/CSPG4 in tumors and angiogenic vasculature was seen to be 
associated with an aggressive disease course in several malignancies, moreover NG2/CSPG4 
is expressed on the surface of both tumor cells and pericytes, and its distribution in normal 
tissues can be considered relatively restricted, so to be proposed as an attractive candidate 
for simultaneously targeting the malignant and stromal cellular compartments within the 
tumour25.  Both the progenitor cells and the tumor cells are mitotic and in some cases highly 
motile. Many researches demonstrate the ability of NG2/CSPG4  to trigger rearrangements 
of the actin cytoskeleton26–28 and to interact with components of the extracellular matrix29–
32, suggesting that NG2/CSPG4 plays a role in both growth control and motility of cells33. 
Because of its structure, distribution, and functions NG2/CSPG4 has been proposed to 
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promote tumor progression by multiple mechanisms and may represent a putative target 
for molecular therapy against cancer. 
 
1.1 Gene-related traits 
 
Human chondroitin sulphate proteoglycan 4 was first identified in 1981 on human 
melanoma cells34, the complete cDNA and the primary amino acid sequences for rat 
ortholog of NG2/CSPG4 have been obtained in 199135, and in 1996 Pluschke and 
collaborators published the human sequence of NG2/CSPG4 expressed by human 
melanoma cells36. The contiguous human cDNA spans 8,071 nucleotides and contains an 
open reading frame of 2,322 amino acids35. The human predicted protein is an integral 
membrane molecule with a large N-terminal extracellular domain (2,221 amino acids), a 
single transmembrane domain (25 amino acids), and a short cytoplasmic tail (76 amino 
acids)35, encoded by a single gene with 10 exons37. To date no alternatively spliced variants 
have been described37. The human NG2/CSPG4 gene is located on Chromosome 15q at 
position 75,966,663-76,005,18938 (Fig. 1A). Sequence analysis shows that the proximal and 
distal regions of 15q share extensive ancient similarity39. Many of the events by which the 
current duplication structure arose have been reconstructed, and from this kind of study 
researchers found that most of the intrachromosomal duplications seem to share a 
common ancestry. Moreover, it has been demonstrated that some remaining gaps in the 
genome sequence are probably due to structural polymorphisms between haplotypes40. 
Data about Single Nucleotide Polymorphism (SNPs) inside NG2/CSPG4 gene have been 
extracted from the dbSNP database (NCBI, National Center for Biotechnology Information, 
Bethesda, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=snp&cmd=search&term=). 
The annotation of each SNP and its frequency in Caucasian populations were assessed in 
dbSNP NCBI and ENSEMBL (http://www.ensembl.org/index.html) databases. The outcome 
obtained from this research is reported in figure 1B. The system collected several 
polymorphisms in NG2/CSPG4 gene: they are above all synonymous or missense variants: 
the latter could yield codons coding for different amino acids compared to the template 
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NG2/CSPG4 sequence. Interestingly there are 5 stop gained SNPs in the region codifying the 
N-terminal portion of the protein, and likely these polymorphisms could cause the synthesis 
of a shorter protein possibly lacking the C-terminal portion compared to the full length one. 
 
 
Figure 1: NG2/CSPG4 gene in silico study. A) Schematic representation of Chromosome 15. NG2/CSPG4 gene in 
genomic location, bands according to Ensembl, locations according to GeneLoc. Gene ID: ENSG00000173546 
Location: Chromosome 15:75966663-76005189:-1. B) Genetic variation with polymorphisms within the gene 
for NG2/CSPG4 . In the figure the gene  is zoomed and shows the SNPs. Color legend of the modifications is on 
the left of the figure. 
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It is noteworthy that the NG2/CSPG4 has conserved its structural and functional properties 
through phylogenetic evolution, so similarity of NG2/CSPG4 with its counterparts in other 
animal species was considered and lead to the observation that the NG2/CSPG4 homologue 
in rat and mouse shares over 80% aminoacid sequence identity with the human sequence, 
and 90% aminoacid identity with each other. Amino acid differences among the three are 
spread throughout the full-length coding sequence of each protein, suggesting that their 
primary structure is evolutionarily conserved11,41. Here we show that the submission of the 
aminoacid sequence of NG2/CSPG4 (Homo sapiens NP_001888.2 chondroitin sulfate 
proteoglycan 4 (NG2/CSPG4)) in MegaBlast (release 2.2.11) leads to the identification of 11 
homologue sequences to the target. Multiple alignments of the elements were generated 
with ClustalW (v.1.83) and visualized with GeneDoc (Figure 2). 
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Figure 2: Alignment of amino acid sequences of NG2/CSPG4 homologues to the human NP_001888.2. 
Sequences were aligned by using CLUSTALW (www.ebi.ac.uk/clustalw) with default settings; the alignment is 
presented by GENEDOC (www.psc.edu/biomed/genedoc) and visualized in modality Summary view. Residues 
on black, dark gray, and light gray backgrounds indicate 100%, 80%, and 60% amino acid similarity, 
respectively. Color shapes of the regions respect the division of the sequence in domain as follows: D1=purple, 
D2=green, D3=light blue, Transmembrane domain=Yellow, Cytoplasmic tail=Pink.  
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Phylogenomics is an important tool for resolving the Tree of Life, and the transcriptome 
data set provides an opportunity to study the evolutionary history of the gene for 
NG2/CSPG4. Phylogenetic analysis was performed using traditional approach, that is a 
multiple sequence alignment (MSA) constructed using Clustal-X version 1.81, followed by 
tree reconstruction using Phylip Package. Our finding of human NG2/CSPG4 gene as sister to 
the clade containing dog, rat and mouse is consistent with recent studies11, even if we could 
observe all the orthologues in the phyologenesis. In the tree of the orthologues shown in 
figure 3, we set Ceanorabditis elegans as outgroup since it is evolutionarily the fairest 
organism from Homo sapiens, moreover it respects the speciation and is coherent with the 
tree of life, since it localizes mammals in the same group in particular, as we expected, 
Homo sapiens and Pan troglodytes (Fig. 3). 
 
Figure 3: Phylogenetic Tree of the 11 sequences found to be homologue to the human protein sequence 
NP_001888.2 chondroitin sulfate proteoglycan 4 (NG2/CSPG4). The tree shows 12 orthologue genes where 
Ceanorabditis elegans has been defined as outgroup, since it is evolutionarily the fairest organism from Homo 
sapiens. As we expected, mammalians are localized in the same group (bold in orange) above all Homo sapiens 
and Pan Troglodytes (bold in red). The tree respects the speciation and it is coherent with the tree of life. Scale 
bar= number of substitutions per site. Bootstrap index are reported above nodes. 
      
 
1.2 Structural and functional characteristics 
NG2/CSPG4 is a chondroitin sulfate proteoglycan with structural characteristics that make it 
unique among members of the proteoglycan family28. Although many proteoglycans can be 
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grouped into families based on structural similarities (syndecans, aggrecans, glypicans, etc.), 
NG2/CSPG4 does not contain structural motifs common to any of these known groupings35. 
NG2/CSPG4 could be expressed on the cell surface both with N-linked chondroitin sulphate 
chain and without any GAG chain, so to be considered a “part-time proteoglycan”37. Figure 4 
represents the aminoacidic sequence and the tertiary predicted structure of human 
NG2/CSPG4 (modified with Swiss Pdb-Viewer from the outcome obtained with SWISS-
MODEL). As shown from this representation, NG2/CSPG4 is a type 1 transmembrane protein 
in which a 25-residue transmembrane domain (aminoacids 2222-2246, in yellow) separates 
a relatively short 76 amino acid C-terminal cytoplasmic domain (2247-2322, in pink) from an 
extensive 2225-residue N-terminal ectodomain that could be divided into three 
subdomains: an N-terminal globular domain (D1, aminoacids 1-640, in purple) stabilized by 
intramolecular disulfide bonding thanks to its 8 cysteins within the sequence35, and 
containing two laminin G-type motifs that might be important for ligand binding41; a central 
extended domain(D2 aminoacids 641-1590, in green) containing the attachment site for the 
chondroitin sulfate chains42, and the binding sites of collagens V and VI30,43; the globular 
juxtamembrane one-third (D3 aminoacids 1591-2221, in light blue)35 containing N-linked 
oligosaccharides that bind galectin-344 and β1 integrins45, and the sites for proteolysis of 
NG2/CSPG4 , leading to its release from the cell surface9,46. This cleavage sites have been 
discovered in 1995 when Nishiyama and collaborators characterized three molecular forms 
of the NG2/CSPG4 core protein expressed by different cell lines46: since then many 
researchers tried to give a significance to the cleavage of NG2 and its physiological and 
pathological implications3, as we delve further. 
Glycosylation of NG2/CSPG4 with chondroitin sulphate (CS) chains occurs in the trans-Golgi 
compartment47. Along the whole extracellular domain sequence there are 15 potential N-
linked glycosylation sites (consensus sequence: NXS/T)48. 
The cytoplasmic domain of NG2/CSPG4 contains several structural features that should be 
critical for the function of the proteoglycan. Its carboxyl terminal tail contains the PDZ 
(postsynaptic density-95/discs large/zona occludens-1) binding motif QYWV, that can 
interact with PDZ domain-containing proteins49 which usually play a scaffolding role. The 
NG2/CSPG4 cytoplasmic domain also contains multiple potential threonine 
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phosphoacceptor sites, including Thr2256/Thr2314 phosphorylated by PCK  and ERK 1/2, 
respectively, that seems to balance migration and proliferation of cells50,51. Finally, there is 
also a proline-rich segment in the C-terminal half of the cytoplasmic domain, which may 
facilitate additional protein–protein interactions26. 
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Figure 4: Human NG2/CSPG4 aminoacidic sequence 
and tertiary structure prediction. Left: the human 
NG2/CSPG4 aminoacidic sequence is reported, where 
domains are highlighted in different colors: D1=purple, 
D2=green, D3=light blue, Transmembrane 
domain=Yellow, Cytoplasmic tail=Pink. Right: The 
tertiary structure has been predicted with SWISS-
MODEL and obtained with the research and alignment 
of the query (NP_001888.2 sequence). From this 
alignment, overlapping of the known structures with 
significative similarity has been performed and a 
predictive PDB file has been obtained (here visualized 
and modified with Swiss Pdb-Viewer and RasMol). The 
same color legend described above was maintained. 
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From the immunoprecipitations of NG2/CSPG4 from melanoma cells followed by 
immunoblotting analysis, it is easy to observe in literature the full length core protein (about 
250kDa), the glycosylated form (about 450 kDa) and smaller molecules: 150 kDa proteins 
and smaller fragments that are proposed to be secreted or retained on the cell 
surface17,46,52. Although little is known about the mechanisms of shedding or the functions 
of shed NG2/CSPG43, it seems likely to play important roles in a number of physiological 
processes53 and many other factors should be involved. Proteolytic shedding of NG2/CSPG4 
results greatly enhanced in several types of injuries such as spinal cord injuries54,55, multiple 
sclerosis56 and tumors. Several studies regarding the expression of NG2/CSPG4 in the 
Central Nervous System (CNS) let suppose that the over-expression of chondroitin sulphate 
proteoglycans (CSPGs) is thought to create an environment non-conducive to axon 
regeneration in the injured CNS and a variety of CSPGs are known to be present at such 
sites, including NG2/CSPG49. Asher and collaborators demonstrated the existence of large 
amounts of shed NG2/CSPG4 in the adult CNS, where is also used as a marker for OPCs9. 
They supposed it could have implications for in axon regeneration. There are evidence 
showing that in cells (juxtamembrane) D3 is to some extent inaccessible and imply that shed 
NG2/CSPG4, in which both inhibitory domains are accessible, would exert a greater axon 
growth-inhibitory effect than cell-associated NG2/CSPG49. The researchers supposed that 
NG2/CSPG4 is involved in Platelet-Derived Growth Factor (PDGF) signaling in OPCs because 
the rate of NG2/CSPG4 shedding increased with cell density and NG2/CSPG4 expression was 
increased in the absence of PDGF9. Ectodomain shedding converts NG2/CSPG4 into a 
diffusible entity able to interact with the growth cone9. It has been demonstrated that 
soluble NG2/CSPG4 released from tumor cells or tumor-associated pericytes can stimulate 
endothelial cell migration in the tumor microenvironment by interacting with galectin-3 and 
α3β1-integrin on the endothelial surface44,57. From a study of the effect of Transforming 
growth factor beta 1 (TGF 1) on melanoma cells differentiation, it had been observed that 
TGFβ1 caused the increasing of synthesis and shedding of NG2-expressing human 
melanoma cells58, even if the role of this events in tumors remains to be determined. 
To identify the conserved protein domains among the organisms, homologues were 
analysed by multiple sequence alignments using the programs ClustalW and GeneDoc. From 
B 
 
 
13 
 
the alignments we could observe that the most conserved regions are: a) Interaction with 
COL6A2 region, (showed in figure 5  obtained with SeqLogos processing), b) Gly/Ser-rich 
(glycosaminoglycan attachment domain) region c)cystein-rich element in domain 1 and 3 of 
the ectodomain; d) phosphosytes in the cytoplasmic domain. Moreover it is evident that 
NG2/CSPG4 is conserved along the whole aminoacid sequence through the Evolution 
History, and this observation underlines that NG2/CSPG4 tertiary structure should be 
conserved too, as it resulted fundamental for its functions (Figure 2). 
Figure 5: SeqLogos (http://weblogo.berkeley.edu/logo.cgi) of the Collagen VI binding region of NG2/CSPG4 
(aminoacid range: 574-1040) obtained from the multiple alignment in Figure 2. Legend: KRH=green, DE=blue, 
AVLIPWFM=red, STNQCGY=black. Most of the positions are conserved among all the organisms, underling that 
the sequence and the folding of this region is particularly important for its functions  
 
1.3 Putative molecular interactors 
 
The singularity of NG2/CSPG4 structure suggests that it might also be unique in terms of its 
ability to participate in inter- and intra-molecular interactions. As a membrane-spanning 
molecule, NG2/CSPG4 has the potential to interact with its cytoplasmic domain, the large 
extracellular portion, and the glycosaminoglycan chain it carries on the core protein to 
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participate in signaling between the extracellular and intracellular compartments of the cell. 
NG2/CSPG4 guides the activation of important survival and growth pathways, in particular it 
is involved in integrin-regulated focal adhesion kinase (FAK), Extracellular signal-Regulated 
Kinases (ERK 1/2), and Phosphatidylinositol-3 kinases/Akt (PI3K/Akt) pathways, so that 
NG2/CSPG4 results implicated in regulating the growth, survival, proliferation, migration, as 
well as invasion of tumors cells45 (Figure 6A and 6B). FAK serves to integrate signaling 
pathways between growth factor receptors and integrins59 and is implicated in facilitating 
cell survival and regulating cell spreading, migration, and invasion60. Integrins, a family of 
heterodimeric adhesion receptors that mediate both cell–ECM and cell–cell adhesion, 
initiate multiple cellular signals that profoundly influence shape, proliferation, 
differentiation, invasion, metastasis, apoptosis, and anoikis61 and it has been proved that 
NG2/CSPG4 acts as a coreceptor for α4β1-integrin to modulate cell adhesion and spreading, 
also to collagens45, by mechanisms dependent on the small Rho family GTPase Cdc42 and 
the adaptor protein p130cas. Both NG2/CSPG4 and α4β1-integrin are involved in modulating 
melanoma cell adhesion, migration, and invasion62. NG2/CSPG4 may stimulate a 
α4β1integrin-mediated adhesion and spreading by recruiting and activating a signaling 
cascade through CDC42, ACK1 and BCAR163. It has been supposed that NG2/CSPG4 could 
promote retraction fiber formation and cell polarization through Rho GTPase activation  
(RhoA, Rac, Cdc42, adptor protein p130cas) in the control of cell motility63: the involvement 
of NG2/CSPG4 seems to lead to the signal transduction pathway activation thanks to the 
activation of this Rho GTPase family proteins. From these evidences it seems that 
NG2/CSPG4 enhances cell spreading and motility on one hand by PAK activated by Rac and 
Cdc42 and in parallel thanks to the tyrosine phosphorylation of p130cas. These kinds of 
interactions have been supported also by to the employment of anti-NG2/CSPG4 
monoclonal antibodies (mAbs), that lead to the hypothesis of the involvement of 
NG2/CSPG4 both in the phosphorylation of other molecules such as pPDK1, pAkt and pErk1, 
and in the activation of PKCα and β-catenin11, in fact also thanks to the CSPG4-blocking mAb 
225.28 it has been demonstrated the involvement of NG2/CSPG4 in in vitro and in vivo 
activation of FAK, ERK1/2, Akt, and the expression of PKC  in tumor cells17. The effectors of 
this signalling pathway are involved in cytoskeleton reorganization and in cell migration62. 
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Other recent studies have been performed to determine the link between NG2/CSPG4 and 
ERK expression and functions, with the relevance that NG2/CSPG4 expression in radial 
growth phase, vertical growth phase, or metastatic cell lines causes activation of ERK1/2, 
enhanced growth and motility which all require the cytoplasmic domain of the NG2/CSPG4 
core protein. NG2/CSPG4 expression in a radial growth phase cell line also seemed to 
promote an epithelial-to-mesenchymal transition64, a process which itself includes typical 
tumorigenic cell changes, such as enhanced migratory capacity, invasiveness, elevated 
resistance to apoptosis, and greatly increased production of ECM components65(Figure 6). 
As we already mentioned, NG2/CSPG4 is able to interact both with components of the 
extracellular matrix and with the actin cytoskeleton. In 1996 Lin and collaborators 
demonstrated that NG2/CSPG4 is anchored to the actin cytoskeleton27. A deeper 
examination of the distribution of NG2/CSPG4 during cell spreading suggests that 
NG2/CSPG4 can associate with two distinct types of actin-containing cytoskeletal structures: 
the first of these are actin- and myosin-containing stress fibers; the second are the radial 
processes extending from the cell periphery, and these projections contain actin, but unlike 
the cytoskeletal stress fibers, they do not contain myosin, and thus are a distinct domain of 
the actin cytoskeleton28. 
It has been investigated the expression of NG2/CSPG4 in microglial cells and its role on 
inflammatory reaction of microglia by analyzing the expression of the proinflammation 
cytokines (interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α)), chemokines (stromal 
cell-derived factor-1α (SDF-1α) and monocyte chemotactic protein-1 (MCP-1)) and inducible 
nitric oxide synthase (iNOS), finding out that NG2/CSPG4 mediates the induction of iNOS 
and inflammatory cytokine expression, but not the chemokine expression in activated 
microglia66. 
In a study dealing with tumor cell adhesion and proteolysis of the extracellular matrix 
proteins surrounding the cells in processes of tumor invasion, it has been determined, by 
antisense inhibition, that NG2/CSPG4 and membrane-type 3 matrix metalloproteinase 
(MT3-MMP) expressed by melanoma cells are required for invasion and degradation of type 
I collagen67. MT3-MMP co-immunoprecipitated with NG2/CSPG4 in melanoma cells cultured 
on type I collagen or laminin. The association between MT3-MMP and NG2/CSPG4 was 
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largely disrupted by removing chondroitin sulfate glycosaminoglycan (CS) from the cell 
surface, suggesting that CSs mediate the association between the two cell surface core 
proteins. It has been shown that MT3-MMP possesses the potential to promote melanoma 
invasion and proteolysis and that the formation of a complex between MT3-MMP and 
NG2/CSPG4 may be a crucial step in activating these processes67. 
In human melanoma cells, NG2/CSPG4 interacts directly with different ECM components, 
such as collagens II29, V45 and VI29, the heparin-binding domain of fibronectin (FN)31,32 
tenascin, and laminin via domains contained within the protein core of NG2/CSPG429, 
altering cellular morphology and proliferation. The best characterized among these ligands 
is type VI collagen29,68,69,70 which allows the proteoglycan to serve as an efficient cell surface 
receptor for ECM. Motility studies show that this interaction is functionally important and 
indicate that binding of type VI collagen to NG2/CSPG4 triggers signaling mechanisms that 
lead to enhanced cell migration26. This interaction has been further characterized using a 
solid phase binding assay in which purified NG2/CSPG4 was shown to bind to pepsin-
solubilized type VI collagen29.  Collectively, the available results support a role for 
NG2/CSPG4 as signal-transducing molecules that initiate or modify intracellular signal 
cascades important for cell adhesion, motility, and invasion (Figure 6).  
From clinical evidence it has been highlighted that BRAF inhibitors induced the regression of 
metastatic lesions in about 70% of the patients affected from melanomas with the 
BRAFV600E mutation71. Ling and collaborators tried to develop a treatment strategy 
combining BRAF inhibitors and inhibitors targeting other signaling components/pathways 
determined to be abnormal in melanoma cells: with this aim they combined a BRAF 
inhibitor with a CSPG4-specific mAb demonstrating that in vitro response magnitude and 
duration of the BRAF inhibitor against BRAFV600E melanoma cells could be significantly 
enhanced by the employed anti-NG2/CSPG4 mAbs71. 
There are evidence of the dependence of NG2/CSPG4 expression and those of Grb272. This is 
a key molecule in intracellular signal transduction that has been found to link activated cell 
surface receptors to downstream targets by binding to specific phosphotyrosine-containing 
and proline-rich sequence motifs73 like those contained in the cytoplasmic tail of 
NG2/CSPG4. Grb2 signaling is critical for cell cycle progression and actin-based cell motility, 
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and consequently, for more complex processes such as epithelial morphogenesis, 
angiogenesis and vasculogenesis73, where also NG2/CSPG4 is involved. 
The galectins are a family of mammalian lectins that contain conserved carbohydrate 
recognition domains (CRDs) responsible for oligosaccharide-dependent ligand binding74. 
Researchers highlighted that the C-terminal carbohydrate recognition domain of galectin-3 
is responsible for binding to the NG2/CSPG4 core protein. Within the NG2/CSPG4 
extracellular domain, the membrane-proximal D3 segment of the proteoglycan contains the 
primary binding site for interaction with galectin-3. The interaction between galectin-3 and 
NG2/CSPG4 is a carbohydrate-dependent one, mediated by N-linked rather than O-linked 
oligosaccharides within the D3 domain of the NG2/CSPG4 core protein. NG2/CSPG4 
stimulates endothelial cell motility and morphogenesis and this function of NG2/CSPG4 
depends on formation of a complex with galectin-3 and integrin to stimulate integrin-
mediated transmembrane signaling44. NG2/CSPG4, galectin-3, and integrin form a 
complex on the endothelial cell surface, and the formation of this tri-molecular complex 
gives to NG2/CSPG4 the ability to activate endothelial cells in EC motility and 
morphogenesis processes57. In conjunction with recent studies demonstrating the early 
involvement of pericytes in angiogenesis, these data suggest that pericyte-derived 
NG2/CSPG4 could be an important factor in promoting EC migration and morphogenesis 
during the early stages of neovascularization57. 
The intracellular domain of NG2/CSPG4 consists of the C-terminal 76 amino acids containing 
the PDZ binding motif QYWV, which binds to the PDZ domain of scaffold proteins such as 
syntenin75,76, MUPP177, and GRIP141,49,78 as summarized in figure 6:  
 Syntenin: a PDZ domain protein that interacts with NG2/CSPG4 in oligodendrocytes, 
where syntenin-1 is necessary for normal rates of cells migration. The association of 
syntenin-1 with NG2/CSPG4, identified in a yeast two-hybrid screen, was confirmed by 
colocalization of both proteins within processes of oligodendroglial precursor cells and by 
co-immunoprecipitation from cell extracts. Syntenin-1 also co-localizes with NG2/CSPG4 
in “co-capping” assays, demonstrating a lateral association of both proteins in live 
oligodendrocytes75. 
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 MUPP1 (Multi-PDZ Domain Protein 1): a yeast two-hybrid screen was employed to 
identify ligands for the cytoplasmic domain of the NG2/CSPG4 and the existence of an 
NG2/CSPG4-MUPP1 interaction in situ is demonstrated by the ability of NG2/CSPG4 
antibodies to co-immunoprecipitate both NG2/CSPG4 and MUPP1 from detergent 
extracts of cells expressing the two molecules. MUPP1 may serve as a multivalent 
scaffold that provides a means of linking NG2/CSPG4 with key structural and/or signaling 
components in the cytoplasm77. 
 GRIP1 (Glutamate receptor-interacting protein 1): it acts as a scaffolding molecule 
clustering NG2/CSPG4 and AMPA receptor in glial progenitor cells41,49. NG2/CSPG4 may 
thus act to position AMPA receptors on glia towards sites of neuronal glutamate 
release78. 
Researchers showed that >90% of embryonic and adult NG2/CSPG4 cells in the adult central 
nervous system express Olig2, a basic helix–loop–helix transcription factor required for 
oligodendrocyte lineage specification. Studies of mice lacking Olig2 function showed a 
failure of NG2/CSPG4 cell development at embryonic and perinatal stages that were 
rescued by addition of a transgene containing the human OLIG2 locus. These findings 
demonstrated a general requirement for Olig2 function in NG2/CSPG4 cell development and 
highlight further roles for Olig2 transcription factors in neural progenitor cells79. More 
recently it has been investigated the role of EGFR in oligodendrocyte regeneration and 
remyelination, characterizing endogenous neural progenitors that are capable of generating 
oligodendrocytes during normal development and after demyelination, identifying the 
molecular signals that enhance oligodendrogenesis from these progenitors80. Through gain- 
and loss-of-function approaches, researchers explored the role of epidermal growth factor 
receptor (EGFR) signaling in adult myelin repair and in oligodendrogenesis in NG2/CSPG4 
and OLIG2 signaling pathway. From the works perfomed, it comes out that EGFR signaling 
regulates oligodendrogenesis and remyelination by progenitors expressing both NG2/CSPG4 
and Olig280. 
There are many evidence of the effects that  various growth factors have on NG2/CSPG4 
activity in signal transduction81. Fibroblast growth factor (FGF)-2 differentially regulates 
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oligodendrocyte progenitor proliferation and differentiation in culture, and modulates gene 
expression of its own receptors, in a developmental and receptor type-specific manner. 
Three FGF receptors (types 1, 2, 3) are expressed in postmitotic, terminally differentiating 
oligodendrocytes82. Perivascular NG2/CSPG4 may serve as a dual modulator of the 
availability/accessibility of FGF at the cell membrane, as well as the resulting FGFR 
transducing activity as it has been demonstrated that in the absence of NG2/CSPG4, cells do 
not sequester FGF2 at the cell surface and therefore are unable to activate FGF receptors, 
leading to low proliferative responses81. The interaction between NG2/CSPG4 and the 
platelet-derived growth factor receptor-α (PDGFRα) on the surface of oligodendrocyte 
precursors and vascular smooth muscle cells had been previoulsly proposed83, and the 
disruption of this interaction with antibody against NG2/CSPG4 resulted in loss of signaling 
capability through the PDGFRα84,85. Paralysis can result from spinal cord injury and one of 
the causes is the local increase of glial cells leading to the formation of a glial scar, and the 
upregulation of CSPGs at the site of injury through which axons are unable to regenerate86. 
NG2/CSPG4 was reported to physically interact with PDGFRα and its ligand PDGFAA, leading 
to enhanced PDGF-AA signaling activity87,88. Moreover PDGF-BB overexpression is able to 
induce NG2/CSPG4 expression in neural precursors89. The above data suggest a potential 
role for the proteoglycan NG2/CSPG4 in gliomagenesis. In addition, from more recent data, 
it has been demonstrated that NG2/CSPG4 is not required for PDGF-BB in the induction and 
progression of glial tumors90. 
Combined immunohistochemical and quantitative Western Blot analysis revealed major 
reductions in levels of core protein expression (>80% for 130-kDa neurocan, 145/80-kDa 
brevican, 300-kDa phosphacan) and immunoreactivity for NG2/CSPG4, neurocan, 
phosphacan and brevican within decorin-treated injuries compared with untreated 
controls91. Decorin pretreatment of meningial fibroblasts in vitro also resulted in a three-
fold increase in neurite outgrowth from co-cultured adult sensory neurons and suppression 
of NG2/CSPG4 immunoreactivity. It has been demonstrated the ability of decorin to 
promote axon growth across acute spinal cord injuries via a coordinated suppression of 
inflammation, NG2/CSPG4 expression and astroglial scar formation91. Inhibitory CSPGs and 
myelin-associated molecules are major impediments to axon regeneration within the adult 
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central nervous system92. The interaction of NG2/CSPG4 and decorin remains to be 
determined even if it seems that their expression patterns have a correlation. 
Using in vitro and in vivo methods, Nolin et al. describe a therapeutic approach based on 
tissue plasminogen activator (tPA), an extracellular protease that converts plasminogen (plg) 
into the active protease plasmin. The researchers showed that tPA and plg both bind to 
NG2/CSPG4 , which functions as a scaffold to accelerate the tPA-driven conversion of plg to 
plasmin. The binding occurs via the tPA and plg kringle domains to domain 2 of the 
NG2/CSPG4 core protein, and it is enhanced in some settings after chondroitinase-mediated 
removal of the NG2/CSPG4 proteoglycan side chains. Once generated, plasmin then 
degrades NG2/CSPG4, both in an in vitro setting using recombinant protein, and in vivo 
models of spinal cord injury93. NG2/CSPG4 may modulate the plasminogen system by 
enhancing plasminogen activation and inhibiting angiostatin94. 
As described above, the complex mechanisms by which NG2/CSPG4 affects melanoma 
progression have started to be defined, in particular the association with other cell surface 
proteins and receptor tyrosine kinases (RTKs) and its central role in modulating the function 
of these proteins. NG2/CSPG4 is essential to the growth of melanoma tumors through its 
modulation of integrin function and enhanced growth factor receptor-regulated pathways 
including sustained activation of ERK 1/2. The activation of integrins, RTK, and ERK 1/2 
function by NG2/CSPG4 modulates numerous aspects of tumor progression95. One 
intriguing report demonstrated that NG2/CSPG4 expression in human melanoma cells is 
epigenetically regulated, involving changes in promoter methylation, although specific 
mechanisms involved in NG2/CSPG4 locus regulation remain to be identified96. As 
transmembrane co-receptor on tumor cells the main mechanism that involves NG2/CSPG4 
in a leading role is the cell migration that we consider more in deep in the next paragraph. 
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Figure 6: NG2/CSPG4 interactors molecules and functional significance. A) NG2/CSPG4 in the middle of the 
figure, shed with the color legend employed in figure2 and 4. Most of the interactors are reported with the 
same legend. ECM=Extracellular Matrix, ColII=Collagen II, ColV=Collagen V, ColVI=Collagen VI, 
integrins, MT3-MMP=Membrane-Type-3 Matrix Metalloproteinase, FAK=Focal Adhesion 
A 
B 
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Kinase, ERK=Extracellular signal-regulated Kinases, GRIP1/2= Glutamate receptor-interacting protein-1/2, 
AMPA=2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid, MUPP1= Multi-PDZ domain protein-1, 
FGF2= fibroblast growth factor-2, PDGFR = Platelet-Derived Growth Factor Receptor- Grb2= Growth factor 
receptor-bound protein-2, BCAR1: breast cancer anti-estrogen resistance-1, CS-chain=Chondroitin sulphate 
chain. B) Here every NG2/CSPG4-interactor shown in A is replaced with the role that this interaction have in 
tumors cells. Most of the interaction reported lead to the regulation of cell migration, adhesion, spreading, 
proliferation. 
 
1.4 Role of NG2/CSPG4 in cell proliferation and motility 
 
Tumor cell invasion and metastasis is highly dependent on dynamic changes in the adhesion 
and migration of the malignant cells. Studies in this area have demonstrated that the 
recognition of extracellular matrix ligands, or adhesion promoting ligands expressed on 
neighboring cells (i.e. counter-receptors), involves complex molecular mechanisms. Some of 
these structures within extracellular matrix components act by binding integrins, whereas 
others bind additional receptors such as cell surface proteoglycans32. The vast catalog of 
cancer cell genotypes is a manifestation of six essential alterations in cell physiology that 
collectively dictate malignant growth: self-sufficiency in growth signals, insensitivity to 
growth-inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis. 
Each of these physiologic changes novel represents the successful breaching of an 
anticancer defense mechanism hardwired into cells and tissues97. The first demonstration 
that NG2/CSPG4 can be important for cell motility came as a result of the finding that 
NG2/CSPG4 is a cell surface ligand for type VI collagen29,43,68,69,98 that binds the extended 
central D2 domain of NG2/CSPG4, as shown by studies in which recombinant deletion 
mutants of NG2/CSPG4 were expressed in rat B28 glioma cells43. Since then several studies 
have been suggesting a role for NG2/CSPG4 in promoting the proliferation and motility that 
are characteristic of both normal progenitor cells and malignant tumor cells43,85,87,99. 
NG2/CSPG4 seems to play a role in effective cell migration and many works on NG2/CSPG4 
showed that melanoma cell attachment and spreading could be inhibited by NG2/CSPG4 
antibodies4,100. In addition NG2/CSPG4 was capable of triggering rearrangement of the actin 
cytoskeleton27,28,101. Along with potentiating growth factor signaling and serving as a cell 
surface receptor for extracellular matrix components, NG2/CSPG4 seems to have the ability 
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to mediate activation of β1-integrins. These molecular interactions would allow the 
proteoglycan to contribute to processes such as cell proliferation, cell motility and cell 
survival, typical of tumor cells53. Post-translational modifications of NG2/CSPG4 provide an 
important means for regulating its interaction with extracellular and cytoplasmic binding 
partners. Phosphorylation and dephosphorylation have proved to be among the most 
versatile and functionally important types of posttranslational modifications102–104. Two 
distinct Threonine phosphorylation events within the cytoplasmic domain of the 
NG2/CSPG4 proteoglycan seem to help to regulate the balance between cellular 
proliferation and motility. Evidences show that protein kinaseC-α could mediate the 
phosphorylation of NG2/CSPG4 at Thr2256, resulting in enhanced cell motility. Extracellular 
signal–regulated kinase seem to phosphorylate NG2/CSPG4 at Thr2314, stimulating cell 
proliferation. The effects of NG2/CSPG4 phosphorylation on proliferation and motility 
should be dependent on β1-integrin activation51. Intriguingly, NG2/CSPG4 phosphorylated 
at Thr2256 was found to be co-localized with α3β1-integrin in broad lamellipodia at the 
leading edges of motile cells53. The phosphorylation at this site changes the distribution of 
NG2/CSPG4 on the cell surface. Whereas non-phosphorylated NG2/CSPG4 is localized to 
small membrane protrusions distributed over most of the cell surface, Thr2256-
phosphorylated NG2/CSPG4 is largely associated with extensive lamellipodia at the cell 
periphery104. This represents a translocation of NG2/CSPG4 from its co-localization with 
α3β1 integrin on apical microprojections in non-motile cells, suggesting that NG2/CSPG4 
phosphorylation at Thr2256 could be responsible for relocation of the NG2/CSPG4-integrin 
complex to lamellipodia, accompanied by increased cell motility53 PKC-α-mediated. Thus 
NG2/CSPG4 phosphorylation at Thr2256
 could be a key step for initiating cell polarization and 
motility51. Previous in vitro and in vivo studies demonstrated the involvement of NG2/CSPG4 
in cell proliferation85,87,99. A key finding with regard to the role of NG2/CSPG4 in cell 
proliferation was that the proteoglycan is capable of binding with high affinity to the growth 
factors FGF2 and PDGF-AA88. Even if heparan sulfate proteoglycans act as co-receptor for 
members of the FGF family with the heparan sulfate chains105, in the case of NG2/CSPG4, 
the core protein rather than the chondroitin sulfate chain is responsible for growth factor 
binding, with putative binding sites scattered throughout the D2 and D3 domains. As both 
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FGF2 and PDGF-AA are critical for expansion of the oligodendrocyte progenitor population, 
it was supposed that NG2/CSPG4 could be important for progenitor responsiveness to these 
two factors84. This was also confirmed by the use of anti-NG2/CSPG4 antibodies that have 
effectively inhibited proliferation of oligodendrocyte progenitors84. Other studies have 
shown that whereas the combined action of FGF2 and PDGF-AA was able to maintain wild 
type progenitors in their undifferentiated state, NG2/CSPG4 null progenitors began the 
process of differentiation even in the presence of the two growth factors. A similar set of 
findings using smooth muscle cell lines has been made by in our laboratory in the case of 
FGF281. In the absence of NG2/CSPG4, cells do not sequester FGF2 at the cell surface and 
therefore are unable to activate FGF receptors81, leading to low proliferative responses. 
Phosphorylation of NG2/CSPG4 also plays a role in cell proliferation. ERK catalyzes 
phosphorylation of NG2/CSPG4 at Thr2314, stimulating cell proliferation
51. The activation of 
α3β1-integrin is also required for this NG2/CSPG4-dependent increase in proliferation and 
NG2/CSPG4 phosphorylated at Thr2314 is co-localized with α3β1 integrin on microprojections 
on the apical cell surface. It has been supposed that two distinct threonine phosphorylation 
events within the cytoplasmic domain of the NG2/CSPG4 proteoglycan seem to regulate the 
cellular balance between proliferation and motility. Evidences show that PKC-α could 
mediate the phosphorylation of NG2/CSPG4 at Thr2256, resulting in enhanced cell motility. 
Extracellular signal–regulated kinase seem to phosphorylate NG2/CSPG4 at Thr2314, 
stimulating cell proliferation. The effects of NG2/CSPG4 phosphorylation on proliferation 
and motility should be dependent on β1-integrin activation51, even if the details of these 
pathways remain to be determined. 
 
1.5 Nature of NG2/CSPG4 isoforms 
 
NG2/CSPG4 has been considered a putative target for immunotherapy against melanoma 
since the early 80’s, and in more recent years several experiments have been performed to 
demonstrate that the inhibition of NG2/CSPG4 in several kinds of tumors leads to cell 
migration blocking6,71,100, adhesion on fibronectin layer decreasing106, reduction of tumors 
aggressiveness17,107–110. Even if NG2/CSPG4 is a widely accepted immunotherapeutic target 
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for several cancer types, no anti-NG2/CSPG4 drug exists against tumors yet. From the 
employment of these mAbs in in vivo and in vitro experiments we could hypothesize the 
existence of different isoforms of the expressed protein among different cell lines. To this 
end table 1 summarize the antibodies employed in different experiments during the last 30 
years. In many studies diverse mAbs have been employed with the aim to investigate the 
molecular and cellular heterogeneity of the NG2/CSPG4 synthesized by human cancer cells. 
The heterogeneity of the epitopes recognized by different mAbs was due, at least partly, to 
glycosylation of the antigen111 but differences in core protein sequence cannot be excluded. 
In most of these works, where researcher tried to correlate the function of NG2/CSPG4 with 
its structural properties, they employed anti-NG2/CSPG4 monoclonal antibodies with the 
aim to block or, at least, interfere with the tumoral cells activities. In 1981 Bumol and 
Reisfeld performed a biosintetic study in M21 human melanoma cells employing the 
antibody 9.2.27 with high specificity for human melanoma cell surfaces. They could detect 
two different proteins: a 250kDa glycoprotein and a 400kDa high molecular weight 
proteoglycan. With these preliminary data they began to understand that the antigenic 
determinant recognized by monoclonal antibody 9.2.27 is located on a glycoprotein-
proteoglycan complex which may have unique implications for the interaction of 
glycoconjugates at the human melanoma tumor cell surface112. In 1987 Ferrone et al 
analyzed for the first time the effect of combinations of monoclonal antibodies to distinct 
determinants of the NG2/CSPG4 on the sensitivity of immunohistochemical assays to stain 
melanoma lesions. They employed mAbs 225.28, 657.9, and 902.5 recognizing distinct 
epitopes of the human high molecular weight melanoma associated antigen (HMW-MAA) to 
investigate the molecular and cellular heterogeneity of the NG2/CSPG4 synthesized by 
human melanoma cells. The mAbs 225.28, 657.9, and 902.5 immunoprecipitated the two 
characteristic components of the NG2/CSPG4 from an extract of human melanoma cells 
Colo38 ,while mAbs 657.9 and 902.5 precipitated Mr 250,000 and 90,000 proteins from the 
culture supernatant of  Colo38 cells. MAb 225.28 precipitated a Mr 250,000 component but 
did not precipitate the Mr 90,000 component. Moreover thanks to a treatment of 
melanoma cells with glycosidases, they could observe that the heterogeneity of the 
epitopes recognized by the three monoclonal antibodies was, at least partly, due to 
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glycosylation of the antigen molecule, as they differentially bound the molecule. Additional 
experiments were then performed to determine the effect of the combination of the three 
anti-NG2/CSPG4 monoclonal antibodies on the staining of cultured melanoma cells and 
surgically removed melanoma lesions and showed heterogeneous distribution of the 
determinants recognized by mAbs 225.28, 657.9, and 902.5 on NG2/CSPG4 synthesized by a 
melanoma cell line111. Three different anti-chondroitin sulphate monoclonal antibodies 
were used also in a study of Caterson and collaborators, each of which recognized a distinct  
epitope in native chondroitin sulphate113. Analyses indicated that these three antibodies 
reacted differently with chondroitin sulphates obtained from different sources, identifying 
three structurally distinct epitopes within chondroitin sulphates113. More significantly, the 
presence and, possibly, the location of these structures within the chondroitin sulphate 
chains varied with the source, developmental status and pathological status of cells that 
produce these molecules113.  Antibodies against specific domains of the NG2/CSPG4 core 
protein have been employed to characterize three distinct molecular species of the 
proteoglycans expressed by different cell lines: in addition to the intact 300-kDa species, 
researcher identified a 290-kDa released form and a 275-kDa cell-associated form of the 
molecule, both of which lack the cytoplasmic domain46. These works put the basis of a study 
where different anti-NG2/CSPG4 mAbs could be employed to identify different isoforms of 
the protein among tumors. 
In 1981, Reisfeld obtained mAb 9.2.27 with high affinity for melanoma cells since it 
recognizes an epitope on the NG2/CSPG4114. This mAb has been widely employed from 
researchers to investigate distribution, structure and role of NG2/CSPG4 among tumors 
such as melanomas, breast cancers, glioblastoma (Tab. 1) and to investigate the putative 
effects that the mAb play in this cells.  Recent findings show that this antibody seems to 
induces cell death in malignant melanoma cells through protein synthesis inhibition 
followed by some morphological and biochemical features of apoptosis115; it seems to have 
a specific cytotoxicity for NG2/CSPG4-positive cells116, and to suppress melanoma tumor 
growth in in vivo models107,108. 
Many anti-idiotypic mAbs have been product and employed for NG2/CSPG4 studies, such as 
TP41.2, TK7-371, MK2-23: they all showed specific blocking activity on different tumors and 
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resulted to be useful instruments for in vivo investigation of NG2/CSPG4 involvement in 
tumorigenesis, metastases and invasion processes (Tab. 1). 
These and many other works listed in table 1 gave evidence of different NG2/CSPG4 forms 
expressed by different tumors: the 300 kDa fully processed form of the NG2/CSPG4 core 
protein, a 290 kDa piece that is secreted or shed into the medium and the 275 kDa piece 
that seems to be retained on the cell surface46,117. It has been proposed that the cleaved 
275 kDa form of NG2/CSPG4 remains associated with the cytoplasmic fragment via a non 
covalent interaction, allowing the larger extracellular fragment to remain at the cell 
surface117. The employment of antibody against NG2/CSPG4 in the last years led to several 
discoveries about the roles of this molecule in cancer development. There are evidence of a 
vaccine against NG2/CSPG4 that can trigger cell-mediated immune responses to this 
antigen, able to target not only tumor cells but also pericytes in the tumor vasculature118. 
Even many bispecific antibody creation have been perfomed such as the atypical molecule 
rM28, a recombinant bispecific single-chain antibody directed to a melanoma-associated 
proteoglycan and to the costimulatory CD28 molecule on human T cells. The presentation of 
a CD28 antibody within a suitable recombinant, bispecific format could result in a “targeted 
supra-agonistic stimulation” of the CD28 molecule, which leads to effective tumor cell killing 
after induction of unspecifically lytic cells119,120. More recently, several bispecific antibodies 
have been generated employing anti-NG2/CSPG4 monoclonal antibodies121 and among 
them a new bispecific T-cell engaging (BiTE) antibody resulted effective on tumor cell 
activities122. This antibody (MCSP-BiTE) binds to NG2/CSPG4 and human CD3, and when 
tested in vitro on human melanoma cell lines, it showed a specific cytotoxic activity against 
NG2/CSPG4-positive melanoma cell lines122. Finally for the first time a fully human scFv-Fc 
anti-NG2/CSPG4-specific antibody has been generated, by combining phage display scFv 
library technology and recombinant DNA cloning technology123.  
In summary, works employing anti-NG2/CSPG4 antibodies highlighted that: mAb 9.2.27 
inhibits FAK activation45, cell adhesion, and spreading124, it induces clustering of NG2/CSPG4 
and increases -integrin signaling; mAb 763.74 is an inhibitory antibodies, above all on 
9.2.27 effects125, and it is considered an anti-tumor antibody thanks to the evidence that it 
can induce a specific humoral response in patients with advanced melanoma and the 
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treatment significantly increased the survival of these patients126,127; mAb 149.53 recognizes 
NG2/CSPG4 on cell membrane without any functional effect128; mAb 225.28 has been tested 
above all on melanoma71,129 and triple-negative breast tumors17 where it has been seen to 
be able to block multiple signaling pathways important to cell growth, migration, and 
survival. NG2/CSPG4 has been shown to play an important role in growth, migration, and 
metastatic dissemination of tumor cells. It was used as a target for immunotherapy of 
melanoma because of its high expression in at least 80% of melanoma lesions with limited 
inter- and intra-lesional heterogeneity and its restricted distribution in normal tissues. Its 
clinical relevance is indicated by the statistically significant increase in survival of melanoma 
patients who developed NG2/CSPG4-specific antibodies following active-specific 
immunotherapy17. 
We aimed to investigate whether NG2/CSPG4-specific mAbs can inhibit tumor recurrence 
and metastases. Our objectives included investigation of the existence of NG2/CSPG4 
isoforms among tumors, as a useful instrument to study the effect of NG2/CSPG4-specific 
mAb on growth, adhesion, and migration of tumor cells, as well as activation of signaling 
pathways important for tumor cell growth, migration, and survival. To obtain new anti-
NG2/CSPG4 mAbs we started a systematical production of mAbs with the Hybridoma 
technology, where immunization has been performed employing the extracellular portion of 
recombinant NG2/CSPG4 protein and from this immunization 63 clones have been selected 
and they have been characterized. We employed these mAbs to establish the expression 
patterns and subcellular distribution of NG2/CSPG4 in high aggressive tumors cells and 
tissues, and to investigate the existence of NG2/CSPG4 isoforms among different tumors. 
The variable reactivity of mAbs against NG2/CSPG4 expressed from diverse cells or tissues, 
let us hypothesize that different isoforms of NG2/CSPG4 are expressed among the different 
tumors. Moreover Yang and collaborators found 18 puntiform differences between 
aminoacidic sequence of NG2/CSPG4 in A375 melanoma cell line and the sequence present 
in data bank GeneBank. One of the substitution found(C631R) may affect the folding of the 
NH2-terminal portion of the protein, which includes the laminin G domains45. Taken 
together, these findings let us hypothesize the existence of isoforms among different cell 
lines. 
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Table 1. Summary of the anti-NG2/CSPG4 antibodies published. 
ANTIBODY 
ANTIBODY TYPE/ 
IMMUNOGEN 
CELLS* BANDING PATTERN FUNCTIONAL EFFECTS 
225.28 Anti-idiotypic 
antibody
111
 
Colo38
2,71,111,129–131 
M21, SK-MEL-28, SK-MEL-
37, 1520, MV3
71
 
GP-1, GP-5, GP-6, and GP-
8
132
 
HS578T, MDA-MB-231, 
MDA-MB-435, and 
SUM149
17
 
280 kDa, 240 kDa, 120 
kDa, 80 kDa over 400 
kDa, 300 - 700 kDa in 
range)
2
, 280 kDa
132
, 
Precipitation of a 250 
kDa component
111
 
-Block of multiple signaling pathways important to cell growth, migration, and survival
71
. 
-Decrease of monocytes and granular eosinophils and increasing of circulating immune 
complexes
133,134
. 
-Antitumor effect on tumor metastases, spontaneous metastasis and tumor recurrence in 
breast cancer models in mice. Antitumor effect in the cell lines and in the mouse models
17
. 
-Inhibition of both tumor metastasis and tumor recurrence after surgical removal of 
orthotopic mammary primary tumors
17
. 
-Enhancement and prolongation the effects of the BRAF inhibitor in melanoma cells
71
. 
657.9 Colo38 human 
melanoma cells
111
 
Colo38
111
 Precipitation of: 250 and 
90 kDa component
111
 
 
902.5 Colo38 human 
melanoma cells
111
 
Colo38
111,129
 Precipitation of: 250 and 
90 kDa component
111
 
 
 
9.2.27 
 
M14 human 
melanoma cells
114
 
FEMX, SKMEL-28,  LOX12, 
Melmet#1, MA-11, T47D, 
U87MG
135
. 
OCM-1, OCM-3, OCM-8, 
Mel202,OMM-1
116
. 
U87MG
136
. 
A375
23,25,44,62 
M21
4,107,108,112,137
. 
Chimpanzee melanoma 
cells
138
. 
M2669-C1, M1477
139,140
.
 
FME
141,142
. 
240, 400 kDa
112
 
97 kDa
143,144 
250 kDa
4,137–144
 
-Activation of caspase-3 and PARP inactivation in FEMX and SKMEL-28 cells
135
. 
-Induction of chromatin condensation in FEMX cells
135
. 
-Specific cytotoxicity for NG2/CSPG4 -positive cells 
116
. 
-Tumor growth suppression in vitro
23
 and in vivo
107–109
. 
-Three of nine malignant melanoma patients receiving the 9.2.27 monoclonal antibody 
showed an increase in antiglobulin titers. In patients developing antiglobulin responses, the 
response was rapid, typically being detectable within 2 weeks
110
. 
 
TP41.2 Anti-idiotypic 
antibody
145
 
Con, Gard, Gor, PPM-Mill, 
Phi, Rob,Hmeso, Ren
6
 
Colo 38
145,146
 
 -Inhibition of cell adhesion resulting in decreased phosphorylation of FAK and Akt, reduced 
expression of cyclin D1 and apoptosis.  
-Reduced cell motility, migration, and invasiveness, and inhibited growth in soft agar. 
-In vivo treatment prevented or inhibited the growth of xenografts in SCID mice, with a 
significant increase in animal survival
6
. 
7.1 Readus 
Cells (human marrow 
stroma cell line)
24
 
 
COS, Pinkney, HeLa cells
24
 
AML patient samples
24,147–
150
 
220- to 240-kDa
24
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763.74 Anti-idiotypic 
antibody
129
 
Colo 38
100,129,131,145,151
, 
MV3
100
, MeWo
131
, MDA-
MB-435
17
, 
S5 and SK-MEL-28
152
 
250kDa
145,152
 
280 kDa, <440 kDa
17
, 
450 kDa
152
 
-Mediated cell-dependent cytotoxicity of melanoma cells
100
. 
-Inhibition of spreading, migration and matrigel invasion of cells
100
. 
-Ability to induce NG2/CSPG4-specific immune responses in BALB/c mice, in mice immunized 
with 763.74 bearing melanoma cells
151
. 
-Low concentration of mAb which reaches tumor lesions in vivo
131
. 
TK7-371 Anti-idiotypic 
antibody
153
 
Colo 38 in BALB/c mice and 
in rabbits
153
 
 -Elicition of a delayed-type hypersensitivity reaction to NG2/CSPG4-bearing cells in syngeneic 
hosts and anti-HMW-MAA antibodies in BALB/c mice and in rabbits. 
-Induction of humoral immunity to self NG2/CSPG4 in patients with melanoma
153
. 
MK2-23 
 
Anti-idiotypic 
antibody
153
 
Colo38
127,145,154–156
  -Induction of a delayed-type hypersensitivity reaction to NG2/CSPG4-bearing melanoma 
cells
154,155
. 
-Immune destruction of melanoma cells and interference with the metastatic potential of 
cells
127
. 
-Reduction in the size of metastatic lesions in patients with malignant melanoma
157,158
. 
155.8 plasma membrane-
enriched 
fraction from human 
malignant melanoma 
cells M14
159
 
M14, L14, Melur cells
159
 250 kDa and a 400 kDa
159
  
149.53 Anti-idiotypic 
antibody
128,129
  
Colo38
129–131
, MeWo
131
, 
GP-1, GP-5, GP-6, GP-8
132
 
280 kDa
132
  
MCSP-BiTE bispecific T-cell 
engaging (BiTE) 
antibody that binds 
to NG2/CSPG4 and 
human CD3
122
 
Melanoma cell lines 
established from 
biopsied/resected 
metastatic lesions
122
 
 Cytotoxic activity in human melanoma cells
122
. 
rM28 Recombinant 
bispecific single-
chain antibody 
directed to 
NG2/CSPG4 and to 
the costimulatory 
CD28 molecule on 
human T
119
 
M21 (HLA A11/24, B15/35, 
DRB 04051/1301) SKMel63 
(HLA A02/23, B49/50, DRB 
04011/0701), Jurkat  cells, 
OvGG
119
. 
 Tumor cell growth prevention
119
. 
scFv-FcC21 scFv-Fc antibody
123
 Colo38, FO-1, M14, M21, 
Melur, MV3, and SK-MEL-
28; LN443; PCI30; MDA-
MB-231 and T47D; PPM-
Mill; T24; PC3; MG-63; JY, 
LG-2, LKT13, Raji; ML-2
123
 
 -In vitro inhibition growth and migration of tumor cells and in vivo growth of human tumor 
xenografts. These effects were mediated by inhibition of the activation of extracellular signal–
regulated kinase and FAK signaling pathways that are critical for tumor cell growth and 
migration, respectively
123
. 
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*Tumor cell lines in table 1 are as follows: 
 
Human melanoma cell lines: Colo38, M14, M21, S5, SK-MEL-28, SK-MEL-37, 1520, MV3, A375, M21, 
FEMX, SKMEL-28,  LOX12, Melmet#1, M2669-C1, M1477, FME, MeWo, SKMel63, Melur, FO-1 
Human uveal melanoma cell lines: OCM-1, OCM-3, OCM-8, Mel202;  
Cell line derived from a human uveal melanoma skin metastasis: OMM-1 
Human breast cancer cell line: MA-1 
Human triple-negative breast cancer cell lines : HS578T, MDA-MB-231, MDA-MB-435, and SUM149 
Human ductal breast epithelial tumor cell line: T47D 
Human glioblastoma multiforme cell line: U87MG 
Human malignant mesothelioma cell lines: Con, Gard, Gor, PPM-Mill, Phi, Rob,Hmeso, Ren 
Human marrow stroma cell line. Pinkney cell line 
Human cervical cancer cell line: HeLa cells 
Human Autologous lymphoblastoid cell line: L14 
Human Ovarian carcinoma cell line: OvGG 
Human glioma cell line: LN443 
Human head and neck squamous cell carcinoma (SCCHN) cell line: PCI30  
Human breast carcinoma cell lines: MDA-MB-231 and T47D 
Human mesothelioma cell line: PPM-Mill 
Human bladder carcinoma cell line: T24 
Human prostate carcinoma cell line: PC3 
Human  osteosarcoma cell line: MG-63 
Human B-lymphoid cell lines: JY, LG-2, LKT13, Raji 
Human myeloid leukemia cell line: ML-2 
Fibroblast-like cell line derived from monkey kidney tissue: COS 
Guinea Pig Melanoma Cells: GP-1, GP-5, GP-6, GP-8  
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2. MATERIALS AND METHODS 
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2.1 In silico studies 
 
- Genomic location of CSPG4 Gene and SNPs identification: research in Ensemble 
(http://www.ensembl.org/index.html) of the Gene ID: ENSG00000173546. 
- CSPG4 Homologues research: submission of the aminoacid sequence of CSPG4 (Homo 
sapiens NP_001888.2 chondroitin sulfate proteoglycan 4 (CSPG4)) in MegaBlast (release 
2.2.11) leads to the identification of 11 homologue sequences to the target. 
Target sequence: Homo sapiens NP_001888.2 chondroitin sulfate proteoglycan 4 (CSPG4). 
Omologue sequences: 
 Pan troglodytes XP_001144835.3 chondroitin sulfate proteoglycan 4 (CSPG4) 
 Bos taurus NP_001179711.1 chondroitin sulfate proteoglycan 4 (CSPG4)  
 Felis catus XP_003986971.1 chondroitin sulfate proteoglycan 4 (CSPG4) 
 Mus musculus NP_620570.2 chondroitin sulfate proteoglycan 4 (CSPG4) 
 Rattus norvegicus NP_112284.1 chondroitin sulfate proteoglycan 4 (CSPG4) 
 Oryctolagus cuniculus XP_002722087.1 chondroitin sulfate proteoglycan 4 
 Canis lupus familiaris XP_544783.3 chondroitin sulfate proteoglycan 4 (CSPG4) 
 Gallus gallus XP_423277.3 chondroitin sulfate proteoglycan 4 
 Danio rerio XP_001923457.2 chondroitin sulfate proteoglycan 4 
 Drosophila melanogaster AAF53672.3 
 Caenorhabditis elegans C48E7.6 
- Alignments: Allignment of aminoacidic sequences of CSPG4 homologues to the human 
NP_001888.2 using CLUSTALW (www.ebi.ac.uk/clustalw) with default settings; the 
alignment is presented by GENEDOC (www.psc.edu/biomed/genedoc) and visualized in 
modality Summary view (Fig. 2). 
SeqLogos (http://weblogo.berkeley.edu/logo.cgi) of the Collagen VI binding region of CSPG4 
(aminoacid range: 574-1040) obtained from the multiple alignment has been performed. 
- Phylogenesis: first the distances (expressed as percent divergence) between all pairs of 
sequence have been calculated from a multiple alignment using CLUSTALW; then the NJ 
method has been applied to the distance matrix. BOOTSTRAP N-J TREE method has been 
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employed. Phylogenetic Tree of the 11 sequences found to be homologue to the human 
protein sequence NP_001888.2 chondroitin sulfate proteoglycan 4 (CSPG4) has been output 
in phylip format and visualized with TeeView (http://www.treeview.net/). The tree was 
rooted setting Ceanorabditis elegans as outgroup, since it is evolutionarily the fairest 
organism from Homo sapiens. 
- NG2/CSPG4 structure prediction: a template selection search was performed using 
BLAST‐P160 against PDB161 database from NCBI interface simultaneously “Template 
Identification Tool” at SWISS‐MODEL interface162 provided by Swiss Institute of 
Bioinformatics was utilized for template selection. In results, 21 significant hits with E‐value 
zero were observed. SWISS‐MODEL server was used to generate models and Swiss Pdb-
Viewer (http://spdbv.vital-it.ch/) was employed to create a PDB file of the predicted tertiary 
structure of NG2/CSPG4. Structure has been visualized and modified with RasMol 
(http://rasmol.org/). 
 
 
2.2 Tissue specimens 
 
Paraffin-embedded of 22 weeks-old human fetal brain tissues and from glioblastoma 
multiforme lesions have been employed. For each kind of tissue, replicates of sixteen fresh 
tissue microtome sections, 10 mm-thick, 80 mm2 wide, were scraped on ice using a wet 
scraper and immersed into the extraction buffer (20 mM Tris-HCl pH 8.8, 2% SDS, 200 mM 
DTT, 7M Urea, 1 tablet of “complete mini” Roche, 0.8 mM Pefabloc® SC). Lysates were 
collected in Eppendorf safe-lock tubes in a final volume of 800μl of extraction buffer and 
sonicated at the following conditions: 5% output, 5 sec pulse and 30 sec break cooling on 
ice,  repeating 24 times to total sonication time of 2 min per sample. The material was then 
heated up to 100°C for 20 min and the extracts clarified for 15 min at 16,000xg at 4°C and 
quantified by the Bradford method163. 
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2.3 Cell lines 
 
Cell lines classification: 
- A375, M2, COLO38: human malignant melanoma cell lines 
- SK-UT-1: human uterus leiomyosarcoma cell line 
- SK-LMS-1: human vulvar leiomyosarcoma cell line 
- 143B: human osteosarcoma sarcoma cell line 
- HT1080: human fibrosarcoma cell line 
Cells listed above were provided by ATCC,  and cultured in DMEM (Dulbecco’s modified 
Eagle’s medium, Lonza BioWhittaker®), low Glucose 1.0 g/L, supplemented with Penicillin 
100 U/ml and Streptomycin 100 U/ml (Pen/Strep, Lonza BioWhittaker®), L-Glutamine 2 mM 
(Lonza BioWhittaker®), 10% (v/v) FBS (Fetal Bovine Serum, Gibco®). 
Producing anti-NG2/CSPG4 mAbs hybridoma cells were cultured in DMEM (Dulbecco’s 
modified Eagle’s medium, Lonza BioWhittaker®), Glucose 4.5 g/L, with Penicillin 100 U/ml 
and Streptomycin 100 U/ml (Pen/Strep, Lonza BioWhittaker®), L-Glutamine 2 mM (Lonza 
BioWhittaker®) added with 20% FBS tested hybridoma serum and 0.01% oxaloacetic acid 
(that favors the Krebs cycle, increasing cellular respiration, thus, encouraging cell 
proliferation and antibody production) at first. By the time the nutrients are diminished to 
10% FBS without oxaloacetic acid. 
 
2.4 Various reagents  
 
Commercial hybridoma cells producing the anti-NG2/CSPG4 mAb B5/M28 were obtained 
from ATCC. The antiserum against β-actin was purchased from Sigma-Aldrich. Anti-
NG2/CSPG4 mAb 9.2.27 MAB2029, Millipore. Anti-FAK and anti-Paxillin, anti-Cofilin, anti-
Fascin, have been purchased by abcam and employed following datasheets. 
Secondary antibodies for immunocytochemistry staining, Alexa 488, Alexa 594 
(mouse/rabbit) have been purchased from LifeTechnologies and employed as advised from 
datasheets. Antibodies employed in Flow Citometry: Mouse IgG-PE Isotype control (cat 
731624 Beckman Coulter), anti-NG2/CSPG4-PE (PN IM3454U-Clone 7,1 BD Biosciences). 
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Mouse anti-human chondroitin sulfate proteoglycan monoclonal antibody (9.2.27 
MAB2029, Millipore). Secondary antibody AlexaFluor488. Chicken anti mouse IgG (H+L) 
from Invitrogen. 
Reagents for apoptosis detection in microplate laser cytometer acumen®eX3: 0,7µg/ml PI 
and 1 µg/ml Hoechst have been employed for nucleous staining of respectively late 
apoptotic and living cells. Early apoptosis was detected employing reagents from Life 
technologies following manufacture specifications: Mitochondrial Membrane Potential 
Apoptosis Kit with Mitotracker™ Red & Annexin V Alexa Fluor®488; PARP FITC Apoptosis Kit 
- FITC Conjugated; CellEvent™ Caspase-3/7 Green Detection Reagent. 
For the immunoprecipitation irrelevant mouse IgG antibody from Sigma has been 
employed.  
 
2.5 Generation of full-length NG2/CSPG4 construct and recombinant protein production 
 
 Gateway® pDEST™26 Vector N-term-X6-His tag has been employed for the gene expression. 
Sequence from 1 to 6552 nucleotides of cDNA has been cloned, as it codes for the 
NG2/CSPG4 ectodomain from aminoacids 1 to 2184. The transfection has been performed 
in Human Embryonic Kidney 293 cells (HEK293) and Chinese hamster ovary cells (CHO) with 
Metafectene, for the production of the protein in an eukaryotic system. Recombinant 
protein has been purified with HisTrap HP columns prepacked with Ni Sepharose (GE Life 
Sciences). 
 
2.6 Antibody production, purification and characterization 
 
Female Balb/c mice were immunized with the recombinant extracellular portion of human 
NG2/CSPG4 (amino acids 1-2184 of the protein inserted into a pEF6V5his vector) produced 
in HEK293 cells by repeated intraperitoneal injections of the immunogen solubilized in 
complete Freud’s adjuvant (Sigma-Aldrich, St Louis, MI, USA). From ELISA screenings of 
hybridoma clones generated by fusion of NS1 murine myeloma cells with spleen cells from 
mice that developed an anti-NG2/CSPG4 immune-response, we selected 63 clones for 
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further characterization. Reactivity traits of the clones were established by immunoblotting, 
using the immunogen, human melanoma cell lysates from A375 and M2 cell lines, and 
human sarcoma SK-UT-1, SK-LMS1, and HT1080NG2+ cell lines (see below). Moreover 
reactivity traits of clones was assayed by cell-E.L.I.S.A., Flow Cytometry, and 
immunocitochemistry. Clones were isotyped using the Pierce® Rapid ELISA Mouse mAb 
Isotyping Kit. Several of the clones were also used for the production of ascites fluids in 
Balb/c or nude mice. mAbs were purified with affi gel protein A (Bio-rad), and finally 
quantified. 
 
2.7 Immunocytochemistry 
 
Cells were seeded on coverslips and fixed with PFA 4% for 20 minutes. In the case of scratch 
assay coupled to immunocytochemistry staining, seeded cells were starved in absence of 
FBS overnight, then a scratch was done on the cells monolayer and after 24 hours of 
migration they were fixed in PFA 4%. Fixed cells were incubated with blocking buffer (5% 
Normal Goat Serum and 10% BSA in PBS) for 30 minutes at room temperature. In 
experiments with labeling inside the cell membrane, cells were permeabilyzed with an 
incubation of 5 seconds in Triton™ X-100 0,1%. Then primary antibodies, fluorescent 
secondary antibodies and Hoechst were applied ad described above. 
 
2.8 Immunoblotting 
 
- Proteins from cells: cells were solubilized at 4°C with RIPA lysis buffer (50mM Tris, pH 7.4; 
150mM NaCl; 0,5% Na-deoxycholate, 0,1% SDS, 1% Nonidet P-40,2mM EDTA, 1 tablet of 
“complete mini” Roche, Pefabloc® SC 0,8mM) for 15 minutes. Lysates were clarified and the 
supernatant containing proteins was transferred to a fresh tube on ice, and quantified. 
- Proteins from tissues: samples were prepared from paraffin-embedded 22 weeks-old 
human fetal brain tissues and from glioblastoma multiforme lesions. For each kind of tissue, 
replicates of sixteen fresh tissue microtome sections, 10 mm-thick, 80 mm2 wide, were 
scraped on ice using a wet scraper and immersed into the extraction buffer (20 mM Tris-HCl 
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pH 8.8, 2% SDS, 200 mM DTT, 7M Urea, 1 tablet of “complete mini” Roche, 0.8 mM 
Pefabloc® SC). Lysates were collected in Eppendorf safe-lock tubes in a final volume of 800μl 
of extraction buffer and sonicated at the following conditions: 5% output, 5 sec pulse and 30 
sec break cooling on ice,  repeating 24 times to total sonication time of 2 min per sample. 
The material was then heated up to 100°C for 20 min and the extracts clarified for 15 min at 
16,000xg at 4°C and quantified by the Bradford method. 
- SDS-PAGE: samples were solubilized in 5X SDS-PAGE loading buffer (250mM Tris-HCl, pH 
6.8, 2.5% SDS; 35% Glycerol, 0.025% (w/v) Bromophenol blue, 125 mM DTT) and resolved 
on Tris-HCl 5% or pre-cast 4-15% linear gradient gels (Bio-Rad), or native PAGE gels (Life 
Technologies, Inc.). Precision Plus Protein™ Dual Xtra standards (2–250 kDa), Unstained 
HiMark Standards (Life Technology Inc.) and Precision Plus Protein DualXtra standards (Bio-
rad) were employed as molecular markers. 
- Blotting: resolved proteins were transferred overnight onto nitrocellulose membranes and 
the membrane were saturated with blocking buffer (5% dry milk in TBS containing 0.1% 
Tween-20). Blocked membranes were incubated with the anti-NG2/CSPG4 mAbs (1:2 – 1:10 
dilution, supernatants, or 1:150 dilution; ascites fluids) in blocking buffer. Membranes were 
incubated for 1 hour at room temperature with secondary antibodies conjugated to HRP 
(Sigma-Aldrich). Immunolabelled bands were visualized with the ECL Plus 
Chemiluminescence detection kit (Bio-rad). A polyclonal antiserum against β-actin was 
employed as a calibrator (diluted 1:400 in TBS-Tween 0,1%), following revealing with the 
secondary anti-rabbit antibodies conjugated to HRP (Sigma-Aldrich). 
Experiments of Western Blotting/Scratch Assay-coupled were performed to study 
NG2/CSPG4 phosphorylation in immunosorted HT1080NG2+ sarcoma cells. HT1080NG2+ were 
seeded in three different plate dishes and treated with different growth conditions, with the 
aim to obtain three different protein expression patterns: 1) A plate dish was seeded with 
medium added with 10% FBS, and once it reached a 80% confluence the extraction of 
proteins was performed according to the protocol mentioned above with RIPA buffer in this 
section. Protein extract reveled the proliferating expression pattern (P). 2) The second dish 
was seeded with the same number of cells with complete growth medium containing 10% 
FBS, but in such a way that they were already at the 95% confluence, when the cells were 
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starved for 24 hours in serum-free medium, to block proliferation. Then a number of 
scratches were made with a small tip. After 48 hours of migration in serum-free medium, 
protein extraction was performed as usual. The protein expression pattern of migrating cells 
was obtained (M). 3) A third dish was seeded as control, following the same procedures 
described in point (2) but the scratch, so we could compare the protein expression pattern 
during the starvation without any scratch (S). Extracted proteins were quantified and 30µg 
for each of three different protein lysates were analyzed in SDS-PAGE using polyacrylamide 
gels (5%), as described above and the Western blotting was performed according to the 
protocol already described. To block the aspecific link of antibodies to the nitrocellulose 
membranes, they were incubated for 30 minutes at room temperature on a shaker using a 
blocking solution containing 2% of BSA. The hybridization with primary antibodies was 
performed over night at 4 °C on a shaker. Antibodies have been used in a 1:1000 dilution in 
5% BSA in TBSTween 0,1%. The two primary antibodies employed were: the antibody anti 
NG2/CSPG4 sc-33038 (Santa Cruz Biotechnology, inc.) that reacts with all phosphorylated 
Threonines of NG2/CSPG4 of human origin; the Phospho-Threonine-X-Arginine Antibody 
#2351 (Cell Signaling Technology®), that detects endogenous levels of proteins containing 
the motive of NG2/CSPG4 belonging the Thr2256 we suppose is phosphorylated during cell 
migration. Then the membranes were incubated with secondary antibody anti-rabbit-HRP 
and the immunocomplexes highlighted by ECL Plus chemiluminescent detection system, as 
already described. 
 
2.9 Cell-E.L.I.S.A. 
 
Fixed cell-E.L.I.S.A.: 
Cells were seeded in 96multiwell plates in complete growth medium (10000 cells/well). 
After the fixation with PFA2% for 30 minutes, the block of endogenous peroxidase have 
been performed with 3% H2O2 for 15 minutes at room temperature. Blocking aspecific sites 
has been performed dosing blocking buffer (PBS con2% di BSA; 10% sucrose; 0,1% NaN3) to 
the cells for 30 minutes at room temperature. Cells were incubated over night at 4°C with 
the anti-NG2/CSPG4 mAbs, diluted as follows: surnatants 1:1 in blocking buffer, ascites 1:50 
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in blocking buffer. Streptavidin/Biotin system (Thermo Scientific TS-125-HR and TM-125-BN) 
and TMB (T4444 Sigma) revelation have been employed for the detection of the binding 
between mAbs and their antigen. They have been employed as recommended by the 
datasheet manufactured. All tests were done in triplicate. 
 
Live cell-E.L.I.S.A.: 
Cells were seeded in 96multiwell plates in complete growth medium (melanoma cells 
cells=25000 cells/well; sarcoma=20000 cells/well). Blocking aspecific sites has been 
performed dosing sterile blocking buffer (PBS con2% di BSA; 10% sucrose) to the cells for 30 
minutes within the cell culture incubator. Then cells were incubated for 2 hours at 37°C with 
the anti-NG2/CSPG4 mAbs, diluted as follows: surnatants 1:1 in blocking buffer, ascites 1:50 
in blocking buffer. After the fixation with PFA 2% for 30 minutes, the block of endogenous 
peroxidase have been performed with 3% H2O2 for 15 minutes at room temperature. 
Streptavidin/Biotin system (Thermo Scientific TS-125-HR and TM-125-BN) and TMB (T4444 
Sigma) revelation have been employed for the detection of the binding between mAbs and 
their antigen. They have been employed as recommended by the datasheet manufactured. 
All tests were done in triplicate. 
 
2.10 Flow Cytometry and cell sorting 
 
 All flow cytometry measurements were performed on a FACSCalibur (Becton Dickinson) and 
10000 gated events were collected for each sample. When cells were used, a gate was set 
during acquisition on the forward scatter (FSC) vs. side scatter (SSC) plot to exclude 
fragment of dead cells.  
 
FACS analysis of sorted cells 
The positivity for CSPG4 was conferred analizing F2 channel at value of 543 for HT1080 cells. 
Cells were detached from flask using EDTA 5mM and washed twicely with PBS and than 
resuspended in PBS at a concentration of 5 x  106 cells/ml. 
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50µl of cells was incubated for 15min at RT with 1µl of mouse IgG-PE or 20µl of antibody 
clone 7.1 + 30µl PBS. Than cells was washed with 2 ml PBS and resuspended in 300µl PBS 
and analyzed. 
 
Cell Sorting 
Cells HT1080 were detached from flask using EDTA 5mM and washed twicely with sorting 
Buffer (EDTA 2mM and BSA 0,5% in PBS without calcium and magnesium). Cells were 
counted (10x106) and resuspended in 240µl of buffer and incubated with 60 µl of Ab anti-
NG2/CSPG4 7.1 for 30 minutes at 4°C, than cells were washed in 10 ml of buffer and 
resuspended in 3 ml of buffer in a sterile vial. Cells were analyzed with FACSAria cell sorter II 
(Becton Dickinson) and data were anlyzed with FACSDiva version 6.1.3. Several controls 
were performed to determine appropriated gates, voltages, flux and compensation. For the 
sorting we collected cells in two tubes: A (NG2/CSPG4 + 355173 cells), B (NG2/CSPG4 - 
4214322 cells). We plated cell and made growth them for some days. Than we analyzed 
again cells with FACS Calibur. Immunosorted cell lines were obtained separating cells 
belonging to the same population of HT1080 according to the expression of NG2/CSPG4 
using the patented MACS® columns and beads conjugated (Myltenyi Biotec GmbH, 
Germany). First, the cells were labeled with the primary anti-NG2/CSPG4 mAb 9.2.27. 
Subsequently, the cells were magnetically labeled with anti-mouse IgG MicroBeads. Then 
the cell suspension was loaded onto MACS® column, which was placed in a magnetic field of 
a MACS separator. The magnetically labeled cells were retained within the column, while 
the unlabeled cells were discarded. After removing the column from the magnetic field, the 
magnetically retained cells could be eluted as the positively selected cell fraction.  
 
2.11 Immunoprecipitation and mass spectrometry 
 
- Protein cross-linking: this procedure has been performed on the cells surface maintaining 
pH=8, employing Thermo Scientific Pierce BS3 (Sulfo-DSS) is bis(sulfosuccinimidyl)suberate 
2mM for 30minutes at room temperature. The reaction was quenched with Tris-HCl 20mM 
pH=7.4 for 15 minutes at romm temperature. 
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- Protein extraction from cells: cells were solubilized at 4°C with Lysis Buffer (50mM Tris-HCl, 
pH 7.4; 150mM NaCl; 0,5% Na-deoxycholate, 1% Nonidet P-40, 1 tablet of “complete mini” 
Roche, Pefabloc® SC 0,8mM) for 20 minutes. Lysates were clarified and each supernatant 
containing proteins was transferred to a fresh tube on ice, and finally quantified by the 
Bradford method. 
- Immunoprecipitation: pre-claring has been performed adding 100µl protein A/G and 5µg 
of irrelevant mouse IgG antibody for each mg of sample protein and incubating for 30 
minutes in agitation on ice. Samples were then centrifuged at 1000 g for 5 minutes at 4°C. 
Pellets were discarded and surnatant were saved for the immunoprecipitation. To each mg 
of proteins 120µl protein A/G were added, then samples were incubated overnight in 
agitation on ice with anti-NG2/CSPG4 purified mAbs at the final concentration of 2,5µg/ml. 
Immunoprecipitated proteins were centrifuged at 1000 g for 5 minutes at 4°C, and washed 
with the lysis buffer twice, always discarding the surnatant, as immunoprecipitated proteins 
remains in the pellet in a mix with protein A/G and anti-NG2/CSPG4 mAb. Finally proteins 
were resuspended in ultrapureMilliQ water and quantified. Then we used to reduce the pH 
of samples to permit the separation of NG2/CSPG4 from the protein A/G and the anti-
NG2/CSPG4 mAb employed for the immunoprecipitation (buffer: 40%Acetonitril, 0,2%TFA, 
4%TCA). Afterwards samples were purified with a microcon (cut-off 50 kDa), to obtain the 
protein in its elution buffer and water in a final volume of about 15-20 µL (final sample 
buffer: 12%ACN; 0,06%TFA; 1,2%TCA). 
- Protein reduction: incubation of samples with 5mM dithiothreitol (DTT) for 1 hour at 60°C. 
- Protein alkylation: incubation of samples with 18mM iodoacetamide (IAA) for 30 minutes 
at 25°C. 
- Trypsin digestion: The complete digestion has been obtained in two step, first adding 16 
µg/ml of trypsin to samples and incubating overnight at 37°C, then adding a second rate of 
enzyme at the same conditions for 8 hours. Reaction was stopped adding 13µl of 1% formic 
acid  to each reaction tube. 
- MALDI-TOF analysis: mass spectra were acquired using a 4800 Plus MALDI TOF/TOFTM 
mass spectrometer. Protein samples were prepared for MALDI-TOF mass spectrometry by 
mixing the sample solution with alpha-cyano-4-hydroxycinnamic acid (HCCA) solution. 1 µl 
 
 
43 
 
of this solution was dried on a metal target, forming cocrystals of matrix and protein. Details 
in sample preparation are given above. Spectra of proteins were calibrated externally using 
a mixture containing  bradykinin fragment 1–7 (m/z 757.3997), angiotensin II (human) (m/z 
1046.5423), P14R (m/z 1533.8582) and ACTH fragment 18–39 (human) (m/z 2465.1989). 
The  mass spectra were acquired in positive mode in the range 700–3500 m/z. Data have 
been analyzed with the Open Source Mass Spectrometry Tool mMass164–166 that permitted 
also the research in MASCOT, a search engine that uses mass spectrometry data to identify 
proteins from primary sequence databases. 
-Search Parameters. Type of search: Peptide Mass Fingerprint; Enzyme: Trypsin; Fixed 
modifications: Carboxymethyl (C); Variable modifications: Phospho (ST); Mass values: 
Monoisotopic; Protein Mass: Unrestricted; Peptide Mass Tolerance: ± 100 ppm; Peptide 
Charge State: 1+; Max Missed Cleavages: 1; Taxonomy: Human (Homo sapiens); Database: 
SwissProt. 
The work flow followed for the analysis is outlined in figure 7. 
 
Figure 7: Work flow followed for the 
proteomic analysis. Three kinds of samples 
were prepared: proteins extracted from tumor 
cells and immunoprecipitated with anti-
NG2/CSPG4 mAbs or the same sample run in a 
SDS-PAGE and extracted from gel. Protein 
extracted from tumor cells, crosslinked with 
BS3, and then immunoprecipitated with anti-
NG2/CSPG4 mAbs, or the same sample run 
into a SDS-page and extracted from the gel. 
Recombinant NG2/CSPG4 ectodomain. 
Samples were digested with trypisn, purified 
and concentrated, and finally analyzed with 
MALDI-TOF. 
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2.12. Functional Studies 
 
2.12.1 Apoptosis Assays 
 
Cells were seeded on 96multiwell plate and in their growth medium (1000 cells/well) and 
starved overnight in DMEM serum-free. The anti-NG2/CSPG4 purified mAbs were dosed on 
cells 18 µg/ml and incubated for 24 hours. Apoptosis markers were  employed as described 
above, and apoptosis has been detected employing the MicroPlate Laser Cytometer 
acumen®eX3. 
 
2.12.2 Cell Adhesion assay 
 
Cells were seeded on Roche E-Plates microelectrode array in their growth medium (25000 
cells/well). Then cells were  starved in DMEM serum free for 24 hours. MAbs administrating 
to starved cells: pure surnatants and diluted 1:100 in hybridoma growth medium ascites 
were used. Real-time monitoring of mAbs effect on cellular adhesion with the xCELLigence 
System (Roche). 
 
2.12.3 Cell Migration assay 
 
Cells were seeded (75000 cells/well) at 90% confluence in 48multiwell plates in their growth 
medium. After the cells were adherent, a 24 hours starvation in serum free medium was 
performed to block cells proliferation. Then a surface incision was practiced at the diameter 
of the well in the longitudinal direction, with a small tip. One wash was performed with PBS 
1X to remove cell debris produced by the operation167,168. Every well was treated with 
different medium as follows: a) antibodies in surnatant were added in their own growth 
medium; b) antibodies in ascites were added 1:200 in the same growth medium used in 
point a.; c) growth medium with irrilevant IgG1 was used as negative control. The multiwell 
plate was placed under the microscope and fotograms of scratches were taken in regular 
intervals of 5 minutes over an extended period of 24 hours. The positions of individual cells 
were then marked in consecutive images, thus tracking positional changes of the cells over 
time. This tracking procedure was performed manually through “point and click” systems169.  
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3.1 Selection of anti-NG2/CSPG4 clones and their characteristics 
By conventional immunization of mice and hybridoma production, 63 clones and their 
subclones have been obtained and subclones were isotypized (Tab. 2). 
 
Table 2. Anti-NG2/CSPG4 mAbs list. Some clones have been subcloned and isotypized. 
CLONE Subclone 
Ig isotype 
 CLONE Subclone 
Ig isotype 
H chain L chain 
 
H chain L chain 
NG 2161A4 -     
 
NG 2164G7 -     
  B11 IgG1 k 
 
  A2 IgGM k 
  C12 IgG1 k 
 
  G4 IgG1 k 
  H12 IgG1 k 
 
  H9 IgG1 k 
NG 2161A8       
 
NG 2164H5       
NG 2161B1       
 
  A8 IgG3 k 
NG 2161C1       
 
  A11 IgG1 k 
NG 2161D2       
 
  B9 IgG1 k 
NG 2161D3       
 
NG 2164H9       
  A7 IgG1 k 
 
NG 2166G4       
  E10 IgG1 k 
 
  A5 IgG1 k 
  G4 IgG1 k 
 
  B9 IgG1 k 
  H9 IgG1 k 
 
  E5 IgG1 k 
NG 2161D4       
 
  G5 IgG3 k 
NG 2161D7 -     
 
NG 2166G2       
  C10 IgG1 k 
 
NG 2172A2       
  D3 IgG1 k 
 
NG 2172B5       
  G1 IgG1 k 
 
NG 2172B12       
  G10 IgG1 k 
 
  C10 IgG1 k 
NG 2161E1       
 
  F10 IgG1 k 
NG 2161F8       
 
  F12 IgG2b k 
NG 2161F9       
 
  G10 IgG2a k 
  C2 IgG1 k 
 
NG 2172C2       
  D2 IgG1 k 
 
NG 2172C3       
  D5 IgG1 k 
 
NG 2172C10       
  E6 IgG1 k 
 
NG 2172C12       
NG 2161G7       
 
NG 2172D6       
NG 2161G8       
 
  B1 IgG1 k 
NG 2161G11       
 
  B2 IgG1 k 
NG 2161H2       
 
NG 2172D11 G12 IgG1 k 
NG 2161H3       
 
NG 2172D12 -     
NG 2161H8       
 
  G10 IgG2a k 
NG 2163A1       
 
  G11 IgG1 k 
NG 2163B1       
 
NG 2172E8       
NG 2163C3       
 
NG 2172E9       
NG 2163D7       
 
NG 2172F4       
NG 2163E9       
 
NG 2172F11       
NG 2163F4       
 
  B9 IgG2a k 
NG 2163H4       
 
  F3 IgM λ 
NG 2164A2       
 
  F9 IgG3 k 
NG 2164A7       
 
  G2 IgG3 k 
NG 2164B6       
 
  G3 IgG3 k 
  B1 IgG1 k 
 
NG 2172G3       
  F3 IgG1 k 
 
NG 2172G4       
  D2 IgG1 k 
 
NG 2172G6       
NG 2164C3       
 
NG 2172H6       
  G8 IgM k 
 
NG 2172H12       
  H10 IgM k 
 
B5M28   IgG2b k 
  H12 IgG1 K 
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The panel of anti-NG2/CSPG4 mAbs obtained have been employed for preliminary 
screenings of expressing-NG2 cells in cell-E.L.I.S.A. experiments on living and fixed cells (SK-
LMS1, SK-UT-1, HT1080NG2+, 143B, A375 and M2 cell lines). The results of these screenings 
are resumed in table 3. Each mAb has different abilities to recognize NG2/CSPG4 on tumor 
cell membrane. Antibodies have different patterns when tested on living cells and on 2% 
PFA-fixed cells: some antibodies, such as mAb 2161D7, are more reactive on their antigen 
when expressed on living cells, while others are more reactive when their antigen is 
expressed on fixed cells. Example of this behavior is mAb 2161A4 that links NG2/CSPG4 on 
SK-UT-1 cells only when they are fixed, while mAb 2161B1 behaves on contrary on A375 
cells. We could observe that no one of the mAbs tested is able to recognize NG2/CSPG4 on 
M2 cells, even if this melanoma cell line expresses very high levels of NG2/CSPG4 (Tab. 3).  
Distribution of NG2/CSPG4 has been detected testing different mAbs on HT1080NG2+ and 
A375 cells(Fig. 8). In immunocytochemistry staining, as expected, we observed the 
distribution of NG2/CSPG4 on the cell membrane of both kinds of tumor cells and a 
different intensity of staining could be due to the efficiency that each antibody has in the 
binding of its antigen. 
As we expected, NG2/CSPG4 is distributed above all on cell membrane, as we can observe 
when immunolocalized by all the positive anti-NG2/CSPG4 mAbs tested, apart from the 
negative results obtained with mAb 2161D2 on both cell lines. In some cases NG2/CSPG4 
seems to immuno-localize in cytoplasmic regions (2161D3, 2164B6, 2172D6, 2166G4, 
2161D7 on both cell lines) and in some other cases in perinuclear districts (2161D3, 2172D6, 
2161D7 on both cell lines tested) (Fig. 8). No one among the tested anti-NG2/CSPG4 mAbs 
could bind to NG2/CSPG4 on M2 cell membrane (data not shown), and this confirms data 
previously obtained from the other screenings. 
Flow Cytometry analysis, performed on several cell lines, confirmed what observed before 
on M2 cells, as no one among the tested antibodies could recognize NG2/CSPG4 expressed 
from this cell line (Tab. 3). Moreover, these screenings gave evidence of a great variability of 
results among the different cell lines studied, with the confirmation of our hypothesis 
concerning the putative existence of many forms cell-line specific of NG2/CSPG4 (Tab.3 and 
Fig. 9). 
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Table 3. NG2/CSPG4 relative expression on different tumors cell membrane. Data are expressed in percentage 
(%) compared to a negative control. n.d.: not determined data. 
  Flow Cytometry cell-ELISA (fixed cells) cell-ELISA (alive cells) 
CLONE SKLMS-1            SKUT-1     COLO38     HT1080NG2+ A375 M2 143B A375           SKUT1         143B M2 A375           SKUT-1          SK-LMS-1 M2 
NG 2161A4 0 0 9,18 3,5 0 0 0 24,6 54,04 37 20,2 38,2 0 23,5 0 
NG 2161B1 59,4 78,8 51,06 89,2 96,8 0 86,1 41,1 37,8 39 0 0 22,325 28,971 0 
NG 2161C1 20,07 8,05 12,15 n.d. n.d. n.d. n.d. 0 0 5,3 0 7,36 4,46 0 0 
NG 2161D2 3,11 11,65 18,8 0 n.d. n.d. n.d. 10,6 1,25 8,55 0 41,6 15 24,7 0 
NG 2161D3 53,6 38,8 11,3 40,4 84 0 31,9 51,9 24,2 47,6 0 66,4 26,4 52,8 0 
NG 2161D4 12,93 0,86 26,83 n.d. n.d. n.d. n.d. 35,9 0 12,9 0 0 2,1 0 0 
NG 2161D7 76,8 46,6 18,5 92,8 92,5 0 58,3 53,8 30,1 38 0 72,9 51,1 48,9 0 
NG 2161E1 59,4 62,2 93,17 77,3 93,6 0 62,5 39,2 22,877 21,0 0 13,7 0 0 0 
NG 2161F8 5,06 0,14 44,13 n.d. n.d. n.d. n.d. 0 0 1,02 0 0 8,97 0 0 
NG 2161F9 49,2 33 88,44 86,9 91 0 28,9 30,5 27,7 40,5 0 60,9 45,4 38,2 0 
NG 2161G7 72,74 3,06 98,84 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 3,81 0 0 0 
NG 2161G8 23,01 3,36 47,46 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0 0 0 0 
NG 2161G11 10,47 9,44 12,74 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0 5,65 0 0 
NG 2161H2 4,3 6,6 97,8 40,4 46,8 0 5,5 39,8 25,15 36 0 4,06 0 0 0 
NG 2161H3 26,99 6,34 7,67 n.d. n.d. n.d. n.d. 54,1 58,01 35 0 4,95 0 6,36 0 
NG 2161H8 82,6 52,2 21,34 95,2 93,6 0 63,8 42,0 49,87 34,4 0 5,12 0 4,69 0 
NG 2163A1 67,49 6,7 39,67 n.d. n.d. n.d. n.d. 49,8 14,79 12,5 19,2 0 0 2,93 0 
NG 2163C3 33,3 18,8 98,29 30,9 80,8 0 13,8 51,2 31,1 24,2 0 6,46 0 6,17 0 
NG 2163D7 42 55,5 42,26 65,4 82,9 0 18 46,1 40,8 39,5 0 62,3 35,3 50,5 0 
NG 2163F4 1,4 5,5 26,15 23,8 7,4 0 0 49,7 32,5 11,4 0 4,35 0 3,53 0 
NG 2163H4 100 65,5 81,38 107,1 87,2 0 76,3 58,4 41,7 49,8 0 14,6 31,59 23,06 0 
NG 2164A2 100 67,7 80,44 98,8 97,8 0 83,3 55,6 45,7 46,2 6,57 6,12 25,62 7,4 0 
NG 2164A7 8,13 16,56 15,26 n.d. n.d. n.d. n.d. 44,9 22,92 32,4 0 13,7 20,99 21,87 0 
NG 2164B6 84 56,6 70,44 92,8 94,6 0 62,5 51,2 25,6 11,4 0 38,3 50,4 42 0 
NG 2164C3 92,7 43,3 81,14 89,2 96,8 0 83,3 42,9 17,2 10,4 0 93,8 33,6 20,1 0 
NG 2164G7 76,8 52,2 88,17 92,8 91,4 0 48,6 42,3 26,91 49,8 0 9,14 12,73 13,4 0 
NG 2164H5 9,36 1,03 10,51 91,5 n.d. n.d. n.d. 0 61,41 20,9 0 5,24 20,18 0 0 
NG 2164H9 10,51 9,1 17,21 n.d. n.d. n.d. n.d. 14,1 22,72 8,88 0 8,77 18,71 15,18 0 
NG 2166G4 3,3 3,8 48,16 25,9 71,2 0 0 40,0 37,01 73,3 0 35,4 16,6 38,28 0 
NG 2166G2 11,16 0,06 8,03 n.d. n.d. n.d. n.d. 
 
11,76 12,5 0 20,0 24,87 30,69 0 
NG 2172A2 47,8 45,5 14,39 75 82,9 0 48,6 3,1 23 31,7 0 40,8 13,46 41,12 0 
NG 2172B5 3,11 13,86 9,98 n.d. n.d. n.d. n.d. 58,9 21 20,9 0 3,05 5,127 30,16 0 
NG 2172B12 63,7 47,7 15,88 94 91,4 0 31,9 3,8 15,34 11,1 0 9,2 30,807 51,57 0 
NG 2172C2 78,2 85,5 33,17 90,4 98,9 0 83,3 6,1 34,1 26,6 0 35,5 21,17 43,79 0 
NG 2172C3 15,9 31,1 41,03 42,8 25,5 0 20,8 0 0,84 12,1 0 28,0 11,65 10,2 0 
NG 2172C10 55 24,4 81,8 64,2 82,9 0 36,1 0 0 31,2 0 2,43 21,61 58,62 0 
NG 2172C12 15,16 13,35 23,73 n.d. n.d. 0 n.d. 46,3 30,7 60,3 0 30,0 18,23 29,93 0 
NG 2172D6 46,3 43,3 53,14 85,7 95,7 0 43 44,3 17,2 20,1 0 33,5 23,01 21,23 0 
NG 2172D12 0 0 12,5 0 0 0 0 0 0 20,8 0 12,5 24,21 0 0 
NG 2172E8 23,11 1,38 45,78 n.d. n.d. n.d. n.d. 38,7 11,6 24,2 0 7,45 17,39 23,47 0 
NG 2172E9 1,56 0,06 17,18 n.d. n.d. n.d. n.d. 46,8 13 22,3 4,54 5,03 10,5 0 0 
NG 2172F4 3,14 4,08 21,64 n.d. n.d. n.d. n.d. 33,3 0 18,1 0 6,73 8,86 0 0 
NG 2172F11 0 0 74,88 0 0 0 0 3,2 14,51 10,3 0 0 23,33 18,42 0 
NG 2172G3 78,2 38,8 90,15 89,2 91,4 0 47,2 0 1,78 0,88 0 23,6 31,52 19,05 0 
NG 2172G4 73,9 33,3 5,16 89,2 93,6 0 38,8 0 0 11,1 0 31,4 50,33 22,34 0 
NG 2172G6 33,3 70 9,84 83,3 79,7 0 31,9 0 0 5,45 0 27,9 40,05 22,34 0 
NG 2172H6 75,3 85,5 87,14 97,6 101 0 69,4 6,3 20,6 7,1 0 18,0 11,91 28,21 0 
NG2172H12 2,14 1,3 15,48 n.d. n.d. n.d. n.d. 42,3 7,64 52,4 0 9,83 13,06 6,16 0 
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Figure 8: Anti-NG2/CSPG4 mAbs immunostaining. Distribution of NG2/CSPG4  on A375 (A) and HT1080
NG2+
 (B) 
4%PFA-fixed cells, shown by immunofluorescence. Zoom 60X. Green= AlexaFluor-488, red= AlexaFluor-594, 
both directed to anti-NG2/CSPG4 primary mAbs. Blue= Hoechst staining of nucleus.  
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From immunochemistry assays we investigated the different isoforms that we hypothesized 
to be expressed by the different cell lines. As many evidence in the past showed that several 
forms of the protein are expressed in tumors (Tab. 1), we compared the reactivity of mAbs 
in different cell lines by Flow Citometry assays as previously resumed in Table 3. Most 
relevant results have been plot in figure 9 where it is possible to observe that anti-
NG2/CSPG4 mAbs employed seem to be able to recognize NG2/CSPG4 with various 
efficiency: for example, analyzing A375 cells, 2172B12 recognizes NG2/CSPG4 better than all 
other mAbs. On the other hand, comparing the level of NG2/CSPG4 recognized by a 
particular mAb on different cell lines we suppose that isoforms of NG2/CSPG4 could exist. 
An antibody could recognize or not a NG2/CSPG4 isoform depending on its specificity. For 
example the mAb 2166G4 recognizes NG2/CSPG4 on A375 cells but not on SK-UT-1 cells: 
perhaps these two cells posses different isoforms of NG2/CSPG4 (Fig. 9). 
 
 
 
Figure 9: Flow Cytometry analysis. Pink: AlexaFluor488, Purple: anti-NG2/CSPG4 mAb + AlexaFluor-488, Green: 
Ab 9.2.27 (Millipore + AlexaFluor-488). 
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Screenings performed by western blotting confirmed what observed on different cell lines 
about different kinds of mAbs recognition of their antigens (Fig. 10). From A375 cell line 
banding pattern we can observe that it expresses mainly two NG2/CSPG4 isoforms: one 
heavier than 250 kDa and the other lighter than 250kDa. The following mAbs recognize both 
the isoforms: 2161F9, 2172D6, 2166G4, 2164H5, 2164B6, 2161D3, 2172A2, 2172E8, 
2161D7. mAbs 2172B12 and 2161D2 recognize the lighter isoform on A375 cells, while mAb 
2161G11 recognize only the heavier isoform. HT1080NG2+ cells do not show the lighter 
isoforms, and some antibodies link to the heavier isoforms: 2161F9, 2172B12, 2172D6, 
2164H5, 2164B6, 2161D3, 2162D7. MAb 2161D2 recognizes only a degraded form of the 
protein (100kDa), while 2161F9 and 2172B12 bind to many isoforms of different weights 
ranging from 250 to 75 kDa. We aimed to test anti-NG2/CSPG4 mAbs on protein lysate 
obtained from tissue specimens of fetal brain and glioblastoma multiforme patients. From 
Western Blot we can observe that 2161F9 binds to the high molecular weight molecule on 
glioblastoma multiforme, while it binds to the lighter molecule on fetal brain. MAbs 2164B6, 
2161D3, 2161D7 and 2166G6 have similar banding pattern on glioblastoma multiforme 
extracts, while 2164C3 mAb binds to lighter forms of the protein, ranging from 100 to 150 
kDa. Results on fetal brain are moderate, and it seems that 2161D3 can not recognize 
NG2/CSPG4 on these tissues, while  2164B6, 2161D7, 2166G4 and 2164C3 have similar 
banding pattern ranging from 250kda to lower molecular weight peptides (Fig. 10).  
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Figure 10: Identification of NG2/CSPG4 isoforms and their proteolytic fragments in cells and tissues. A) 
Identification of NG2/CSPG4 isoforms and their proteolytic fragments in tumors cell lysates (A375, HT1080
NG2+
) 
and in recombinant NG2/CSPG4 (NG2
rec
) used for producing the mAbs. Proteins were resolved by SDS-PAGE 
under reducing conditions on 5% or 4-15 gradient gels, followed by transferring onto nitrocellulose 
membranes and immunoblotting with the indicated anti-NG2/CSPG4 mAbs. Relative position of molecular 
weight markers is indicated to the side of each panel. B) Identification of NG2/CSPG4 isoforms and their 
proteolytic fragments in pericyte sprouts of fetal brain neovessels and in glioblastoma multiforme lesions 
(GMB). Sections from brain areas taken adjacently to sections with abundant angionenesis and enrichment of 
Figure 2: Western blot screening of anti-NG2 mAbs on cells lysates
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NG2/CSPG4 -expressing pericytes, and lysates of GMB were solubilized and the material threated as in A. A375 
melanoma cells, and the NG2
rec
 were blotted in parallel for reference. Immunoblotting of β actin with a 
commercial polyclonal ab was used for normalization of gel lane loading. Relative position of molecular weight 
markers is indicated to aside each panel.       
 
 
3.2 Characterization of isoforms and their interacting molecular partners 
 
As a transmembrane molecule with co-receptor functions, NG2/CSPG4 has the potential to 
interact with both extracellular and cytoplasmic components and to participate in signaling 
between the extracellular and intracellular compartments of the cell, therefore it is 
considered a central factor in controlling the consequences of microenvironment on tumors 
progression. With the aim to find new molecular NG2/CSPG4-interactors, a proteomic 
analysis of A375 melanoma cells have been performed. Three kinds of samples were 
prepared: 1) proteins extracted from tumor cells and immunoprecipitated with anti-
NG2/CSPG4 mAbs or the same sample run in a SDS-PAGE and extracted from gel. 2) Protein 
extracted from tumor cells, crosslinked with BS3, and then immunoprecipitated with anti-
NG2/CSPG4 mAbs, or the same sample run into a SDS-PAGE and extracted from the gel. 3) 
Recombinant NG2/CSPG4 ectodomain (NG2rec).  
 
 
Figure 11: A) Preliminary western blotting to test the efficiency of immunoprecipitation (IP NG2/CSPG4 ) and of 
the crosslinking with BS3 (IP NG2/CSPG4 +BS3) employing NG2
rec
 as reference. Proteins were resolved by SDS-
PAGE under reducing conditions on 5% gels, transferred onto nitrocellulose membranes and incubated with 
anti-NG2/CSPG4 mAb 2161D3. B) Coomassie-stained SDS-PAGE gel employed for protein extraction from gel 
and employment of samples for MALDI-TOF analysis. Proteins were resolved by SDS-PAGE under reducing 
conditions on 5% gels. 
 
 
Samples were digested with trypsin, purified and concentrated, and finally analyzed with 
MALDI-TOF Mass Spectrometry. Figure 12A shows a pilot experiment performed as control. 
It shows the MALDI-TOF mass spectrum of peptides obtained form trypsin digestion of 
NG2rec  with a mass of 236936,5±1100 Da. The research in MASCOT confirmed the obtaining 
A B 
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of NG2/CSPG4 from this analysis. Figure 12B shows the spectrum of the peptide mass 
fingerprint of NG2/CSPG4 immunoprecipitated from A375 cells with anti-NG2/CSPG4 mAb 
2161D3. The analysis with mMass and the research in MASCOT of the peaks led to the 
CSPG4_HUMAN achievement among the results (shown in green dots on the B spectrum, 
Fig. 12B). Figure 12C shows the spectrum of the peptide mass fingerprint of NG2/CSPG4 
crosslinked with BS3 before the immunoprecipitation procedure from A375 total cell lysate. 
The analysis with mMass and the research in MASCOT of the peaks values let us obtain the 
CSPG4_HUMAN (shown in green dots on the spectrum) and a list of many other molecules 
with high score (over 50) that could be considered as putative interactors of NG2/CSPG4: 
 
 Integrin beta-5 (ITB5): it is a receptor for fibronectin. Values matched: 28. Protein 
sequence coverage: 28%. 
 Microtubule-associated protein 2 (MAP2): the exact function of MAP2 is unknown but 
MAPs may stabilize the microtubules against depolymerization. They also seem to have a 
stiffening effect on microtubules170. Values matched: 33. Protein sequence coverage: 
24%. 
 Alpha actin 3 (ACTN3): cross-linking protein which helps to anchor the myofibrillar actin 
filaments to a variety of intracellular structures171. Mass values matched: 29. Protein 
sequence coverage: 34%. 
 Actin related protein (ARP3B): it plays a role in the organization of the actin 
cytoskeleton. It may function as ATP-binding component of the Arp2/3 complex which is 
involved in regulation of actin polymerization and together with an activating nucleation-
promoting factor (NPF) mediates the formation of branched actin networks. ARP3B 
seems to decrease the metastatic potential of tumors172. Values matched: 13. Protein 
sequence coverage: 31%. 
 Myosin-14 (MYH14): a cellular myosin that appears to play a role in cytokinesis, cell 
shape, and specialized functions such as secretion and capping173. Mass values matched: 
53. Protein sequence coverage: 28%. 
 Myomesin-2 (MYOM2): it is a 150KDa protein with undefined function. It contains 5 
fibronectin type-III domains. Values matched: 52. Protein sequence coverage: 36%. 
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 von Willebrand factor A domain-containing protein 5A (VMA5A): it may play a role as a 
tumor suppressor. Altered expression of this protein and disruption of the molecular 
pathway it is involved in, may contribute directly to modify tumorigenesis174. Mass values 
matched: 23. Protein sequence coverage: 36%. 
 Spectrin alpha chain, non-erythrocytic 1 Protein (SPTN1): it seems to be involved in 
secretion, interacts with calmodulin in a calcium-dependent manner and is thus 
candidate for the calcium-dependent movement of the cytoskeleton at the 
membrane175. Mass values matched: 49. Protein sequence coverage: 22%. 
 Plexin-A4 (PLXA4): a coreceptor for SEMA3A, necessary for signaling by class 3 
semaphorins and subsequent remodeling of the cytoskeleton. It plays a role in axon 
guidance in the developing nervous system. Class 3 semaphorins bind to a complex 
composed of a neuropilin and a plexin. This plexin modulates the affinity of the complex 
for specific semaphorins, and its cytoplasmic domain is required for the activation of 
down-stream signaling events in the cytoplasm. It is a single-pass type I transmembrane 
protein176. Recent studies show that Plexin-A4 promotes tumor progression and tumor 
angiogenesis by enhancement of VEGF and bFGF signaling177. Mass values matched: 37. 
Protein sequence coverage: 23%. 
 Plasminogen-like protein A (PLGA): a secreted protein that may bind non-covalently to 
lysine binding sites present in the kringle structures of plasminogen. This may interfere 
with the binding of fibrin or alpha-2-antiplasmin to plasminogen and may result in the 
localization of activity at sites necessary for extracellular matrix destruction178,179. Mass 
values matched: 9. Protein sequence coverage: 54%. 
 Synemin (SYNEM): it is a Type-VI intermediate filament (IF) which plays an important 
cytoskeletal role forming heteropolymeric IFs with desmin and/or vimentin. It interacts 
with cytoskeletal proteins including: alpha-dystrobrevin, dystrophin, talin-1, utrophin and 
vinculin. SYNEM is able to link these heteropolymeric IFs to adherens-type junctions180–
182. Mass values matched: 27. Protein sequence coverage: 20%. 
 Periostin (POSTN): it binds to heparin. Induces cell attachment and spreading and plays a 
role in cell adhesion. May govern extracellular matrix mineralization. It has been found to 
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be secreted in the extracellular space reaching the extracellular matrix183–185. Mass values 
matched: 21. Protein sequence coverage: 32%. 
 Heparan sulfate glucosamine 3-O-sulfotransferase 3A1 (HS3SA): a single-pass type II 
membrane protein that catalyzes the transfer of a sulfo group to an N-unsubstituted 
glucosamine linked to a 2-O-sulfo iduronic acid unit on heparan sulfate186. Mass values 
matched: 22. Protein sequence coverage: 53%. 
 ERC protein 2 (ERC2): it interacts through its C-terminus with the PDZ domain PDZ-
containing proteins. It is a cytoplamic protein distributed in cell junction and associated 
to cytoskeleton187. Values matched: 38. Protein sequence coverage: 38%. 
 Zinc Finger (ZF) proteins : ZNF510, ZNF624, ZNF658B, ZNF880, ZNF510, ZNF2, ZNF221, 
ZNF639, ZNF736, ZNF559, ZNF10, ZNF217, ZNFBTB, ZNF672, ZNF441, ZNF595, ZNF16, 
ZNF71, PR domain ZNF protein. 
 
The two spectra in B and C are very similar, a part from some peaks that resulted to be 
peculiar of the sample run in 12C. For a deeper analysis, we followed the Workflow of cross-
link search with the ion-tag model188: from the peaks values list of IP-NG2/CSPG4 +BS3 
(NG2/CSPG4 threated with a crosslinking agent), the common values obtained from IP-
G2/CSPG4 (NG2/CSPG4 alone without any crosslinkation) have been subtracted and a new 
research in MASCOT has been performed with the pick values of the sample that was 
subjected to crosslinking. The results obtained are listed below and show important 
putative interactors of NG2/CSPG4 such as:  
 
 Fascin (FSCN1): a 55 kDa actin-bundling protein, that plays a role in the organization of 
actin filament bundles and the formation of microspikes, membrane ruffles, and stress 
fibers. It has been demonstrated to play a fundamental role in the formation of a diverse 
set of cell protrusions, such as filopodia, involved in cell motility and migration189–192. 
Mass values matched: 27. Protein sequence coverage: 46%. 
 LIM domain and actin-binding protein (LIMA1): it binds to monomers and filaments of 
actin. LIMA1 increases the number and size of actin stress fibers and inhibits membrane 
ruffling. Inhibits actin filament depolymerization. Bundles actin filaments, delays filament 
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nucleation and reduces formation of branched filaments193. This cytoskeletal protein co-
localizes with actin stress fibers and focal adhesion plaques193,194. Mass values matched:  
40. Protein sequence coverage: 46%. 
 Metalloreductase (STEAP3): a six-pass membrane protein that localizes to vesicular-like 
structures at the plasma membrane and around the nucleus. Mass values matched: 6. 
Protein sequence coverage: 13%. 
 Erlin-1 (ERLN1): a component of the ERLIN1/ERLIN2 complex which mediates the 
endoplasmic reticulum-associated degradation (ERAD) of inositol 1,4,5-trisphosphate 
receptors (IP3Rs). ERLN1 is a endoplasmic reticulum membrane, a single-pass type II 
membrane protein that has been found in associated with lipid raft-like domains of the 
endoplasmic reticulum membrane and of cell membran195–197. Mass values matched: 7. 
Protein sequence coverage: 24%. 
 Galectins (Leg9b or leg9c): this is a family of proteins known to carry out intra- and 
extracellular functions, including inhibition of chronic inflammations, GVHD, and allergic 
reactions, through glycoconjugate-mediated recogntion. From the cytosol they may be 
secreted by non-classical pathways, but they may also be targeted to the nucleus or 
specific sub-cytosolic sites. Mass values matched: 4. Protein sequence coverage: 14%. 
 Coiled-coil domain-containing proteins: CC121, CCD18, TMC04, C144B, CCDC8. 
 
These molecules seem to interact with NG2/CSPG4 weakly respect to those listed before, as 
their identification was obtained thanks to the employment of a crosslinking agent.  
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Figure 12: MALDI-TOF spectra. A) NG2/CSPG4
rec
 trypsin digested. B) NG2/CSPG4 extracted from A375 cells and 
immunoprecipitated with anti-NG2/CSPG4 mAb 2161D3, finally digested with trypsin. C) NG2/CSPG4 
crosslinked on A375 cells membrane with BS3, extracted from cells, immunoprecipitated with anti-NG2/CSPG4 
mAb 2161D3 and finally digested with trypsin. 
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Table 4: MASCOT results. Sequences of the outputs with their match values and protein sequence coverage. 
Matched peptides shown in bold. 
ITB5 Value matched=22 Protein sequence coverage=24% MYH14 Value matched=53 Protein sequence coverage=28%
1 MPRAPAPLYA CLLGLCALLP RLAGLNICTS GSATSCEECL LIHPKCAWCS 1 MAAVTMSVPG RKAPPRPGPV PEAAQPFLFT PRGPSAGGGP GSGTSPQVEW
51 KEDFGSPRSI TSRCDLRANL VKNGCGGEIE SPASSFHVLR SLPLSSKGSG 51 TARRLVWVPS ELHGFEAAAL RDEGEEEAEV ELAESGRRLR LPRDQIQRMN
101 SAGWDVIQMT PQEIAVNLRP GDKTTFQLQV RQVEDYPVDL YYLMDLSLSM 101 PPKFSKAEDM AELTCLNEAS VLHNLRERYY SGLIYTYSGL FCVVINPYKQ
151 KDDLDNIRSL GTKLAEEMRK LTSNFRLGFG SFVDKDISPF SYTAPRYQTN 151 LPIYTEAIVE MYRGKKRHEV PPHVYAVTEG AYRSMLQDRE DQSILCTGES
201 PCIGYKLFPN CVPSFGFRHL LPLTDRVDSF NEEVRKQRVS RNRDAPEGGF 201 GAGKTENTKK VIQYLAHVAS SPKGRKEPGV PGELERQLLQ ANPILEAFGN
251 DAVLQAAVCK EKIGWRKDAL HLLVFTTDDV PHIALDGKLG GLVQPHDGQC 251 AKTVKNDNSS RFGKFIRINF DVAGYIVGAN IETYLLEKSR AIRQAKDECS
301 HLNEANEYTA SNQMDYPSLA LLGEKLAENN INLIFAVTKN HYMLYKNFTA 301 FHIFYQLLGG AGEQLKADLL LEPCSHYRFL TNGPSSSPGQ ERELFQETLE
351 LIPGTTVEIL DGDSKNIIQL IINAYNSIRS KVELSVWDQP EDLNLFFTAT 351 SLRVLGFSHE EIISMLRMVS AVLQFGNIAL KRERNTDQAT MPDNTAAQKL
401 CQDGVSYPGQ RKCEGLKIGD TASFEVSLEA RSCPSRHTEH VFALRPVGFR 401 CRLLGLGVTD FSRALLTPRI KVGRDYVQKA QTKEQADFAL EALAKATYER
451 DSLEVGVTYN CTCGCSVGLE PNSARCNGSG TYVCGLCECS PGYLGTRCEC 451 LFRWLVLRLN RALDRSPRQG ASFLGILDIA GFEIFQLNSF EQLCINYTNE
501 QDGENQSVYQ NLCREAEGKP LCSGRGDCSC NQCSCFESEF GKIYGPFCEC 501 KLQQLFNHTM FVLEQEEYQR EGIPWTFLDF GLDLQPCIDL IERPANPPGL
551 DNFSCARNKG VLCSGHGECH CGECKCHAGY IGDNCNCSTD ISTCRGRDGQ 551 LALLDEECWF PKATDKSFVE KVAQEQGGHP KFQRPRHLRD QADFSVLHYA
601 ICSERGHCLC GQCQCTEPGA FGEMCEKCPT CPDACSTKRD CVECLLLHSG 601 GKVDYKANEW LMKNMDPLND NVAALLHQST DRLTAEIWKD VEGIVGLEQV
651 KPDNQTCHSL CRDEVITWVD TIVKDDQEAV LCFYKTAKDC VMMFTYVELP 651 SSLGDGPPGG RPRRGMFRTV GQLYKESLSR LMATLSNTNP SFVRCIVPNH
701 SGKSNLTVLR EPECGNTPNA MTILLAVVGS ILLVGLALLA IWKLLVTIHD 701 EKRAGKLEPR LVLDQLRCNG VLEGIRICRQ GFPNRILFQE FRQRYEILTP
751 RREFAKFQSE RSRARYEMAS NPLYRKPIST HTVDFTFNKF NKSYNGTVD 751 NAIPKGFMDG KQACEKMIQA LELDPNLYRV GQSKIFFRAG VLAQLEEERD
801 LKVTDIIVSF QAAARGYLAR RAFQKRQQQQ SALRVMQRNC AAYLKLRHWQ
851 WWRLFTKVKP LLQVTRQDEV LQARAQELQK VQELQQQSAR EVGELQGRVA
MAP2 Value matched=33 Protein sequence coverage=24% 901 QLEEERARLA EQLRAEAELC AEAEETRGRL AARKQELELV VSELEARVGE
1 MADERKDEAK APHWTSAPLT EASAHSHPPE IKDQGGAGEG LVRSANGFPY 951 EEECSRQMQT EKKRLQQHIQ ELEAHLEAEE GARQKLQLEK VTTEAKMKKF
51 REDEEGAFGE HGSQGTYSNT KENGINGELT SADRETAEEV SARIVQVVTA 1001 EEDLLLLEDQ NSKLSKERKL LEDRLAEFSS QAAEEEEKVK SLNKLRLKYE
101 EAVAVLKGEQ EKEAQHKDQT AALPLAAEET ANLPPSPPPS PASEQTVTVE 1051 ATIADMEDRL RKEEKGRQEL EKLKRRLDGE SSELQEQMVE QQQRAEELRA
151 EDLLTASKME FHDQQELTPS TAEPSDQKEK ESEKQSKPGE DLKHAALVSQ 1101 QLGRKEEELQ AALARAEDEG GARAQLLKSL REAQAALAEA QEDLESERVA
201 PETTKTYPDK KDMQGTEEEK APLALFGHTL VASLEDMKQK TEPSLVVPGI 1151 RTKAEKQRRD LGEELEALRG ELEDTLDSTN AQQELRSKRE QEVTELKKTL
251 DLPKEPPTPK EQKDWFIEMP TEAKKDEWGL VAPISPGPLT PMREKDVFDD 1201 EEETRIHEAA VQELRQRHGQ ALGELAEQLE QARRGKGAWE KTRLALEAEV
301 IPKWEGKQFD SPMPSPFQGG SFTLPLDVMK NEIVTETSPF APAFLQPDDK 1251 SELRAELSSL QTARQEGEQR RRRLELQLQE VQGRAGDGER ARAEAAEKLQ
351 KSLQQTSGPA TAKDSFKIEE PHEAKPDKMA EAPPSEAMTL PKDAHIPVVE 1301 RAQAELENVS GALNEAESKT IRLSKELSST EAQLHDAQEL LQEETRAKLA
401 EHVMGKVLEE EKEAINQETV QQRDTFTPSG QEPILTEKET ELKLEEKTTI 1351 LGSRVRAMEA EAAGLREQLE EEAAARERAG RELQTAQAQL SEWRRRQEEE
451 SDKEAVPKES KPPKPADEEI GIIQTSTEHT FSEQKDQEPT TDMLKQDSFP 1401 AGALEAGEEA RRRAAREAEA LTQRLAEKTE TVDRLERGRR RLQQELDDAT
501 VSLEQAVTDS AMTSKTLEKA MTEPSALIEK SSIQELFEMR VDDKDKIEGV 1451 MDLEQQRQLV STLEKKQRKF DQLLAEEKAA VLRAVEERER AEAEGREREA
551 GAATSAELDM PFYEDKSGMS KYFETSALKE EATKSIEPGS DYYELSDTRE 1501 RALSLTRALE EEQEAREELE RQNRALRAEL EALLSSKDDV GKSVHELERA
601 SVHESIDTMS PMHKNGDKEF QTGKESQPSP PAQEAGYSTL AQSYPSDLPE 1551 CRVAEQAAND LRAQVTELED ELTAAEDAKL RLEVTVQALK TQHERDLQGR
651 EPSSPQERMF TIDPKVYGEK RDLHSKNKDD LTLSRSLGLG GRSAIEQRSM 1601 DEAGEERRRQ LAKQLRDAEV ERDEERKQRT LAVAARKKLE GELEELKAQM
701 SINLPMSCLD SIALGFNFGR GHDLSPLASD ILTNTSGSMD EGDDYLPATT 1651 ASAGQGKEEA VKQLRKMQAQ MKELWREVEE TRTSREEIFS QNRESEKRLK
751 PALEKAPCFP VESKEEEQIE KVKATGEEST QAEISCESPF LAKDFYKNGT 1701 GLEAEVLRLQ EELAASDRAR RQAQQDRDEM ADEVANGNLS KAAILEEKRQ
801 VMAPDLPEML DLAGTRSRLA SVSADAEVAR RKSVPSETVV EDSRTGLPPV 1751 LEGRLGQLEE ELEEEQSNSE LLNDRYRKLL LQVESLTTEL SAERSFSAKA
851 TDENHVIVKT DSQLEDLGYC VFNKYTVPLP SPVQDSENLS GESGTFYEGT 1801 ESGRQQLERQ IQELRGRLGE EDAGARARHK MTIAALESKL AQAEEQLEQE
901 DDKVRRDLAT DLSLIEVKLA AAGRVKDEFS VDKEASAHIS GDKSGLSKEF 1851 TRERILSGKL VRRAEKRLKE VVLQVEEERR VADQLRDQLE KGNLRVKQLK
951 DQEKKANDRL DTVLEKSEEH ADSKEHAKKT EEAGDEIETF GLGVTYEQAL 1901 RQLEEAEEEA SRAQAGRRRL QRELEDVTES AESMNREVTT LRNRLRRGPL
1001 AKDLSIPTDA SSEKAEKGLS SVPEIAEVEP SKKVEQGLDF AVQGQLDVKI 1951 TFTTRTVRQV FRLEEGVASD EEAEEAQPGS GPSPEPEGSP PAHPQ
1051 SDFGQMASGL NIDDRRATEL KLEATQDMTP SSKAPQEADA FMGVESGHMK
1101 EGTKVSETEV KEKVAKPDLV HQEAVDKEES YESSGEHESL TMESLKADEG MYOM2 Value matched=52 Protein sequence coverage=36%
1151 KKETSPESSL IQDEIAVKLS VEIPCPPAVS EADLATDERA DVQMEFIQGP 1 MSLVTVPFYQ KRHRHFDQSY RNIQTRYLLD EYASKKRAST QASSQKSLSQ
1201 KEESKETPDI SITPSDVAEP LHETIVSEPA EIQSEEEEIE AQGEYDKLLF 51 RSSSQRASSQ TSLGGTICRV CAKRVSTQED EEQENRSRYQ SLVAAYGEAK
1251 RSDTLQITDL GVSGAREEFV ETCPSEHKGV IESVVTIEDD FITVVQTTTD 101 RQRFLSELAH LEEDVHLARS QARDKLDKYA IQQMMEDKLA WERHTFEERI
1301 EGESGSHSVR FAALEQPEVE RRPSPHDEEE FEVEEAAEAQ AEPKDGSPEA 151 SRAPEILVRL RSHTVWERMS VKLCFTVQGF PTPVVQWYKD GSLICQAAEP
1351 PASPEREEVA LSEYKTETYD DYKDETTIDD SIMDADSLWV DTQDDDRSIM 201 GKYRIESNYG VHTLEINRAD FDDTATYSAV ATNAHGQVST NAAVVVRRFR
1401 TEQLETIPKE EKAEKEARRS SLEKHRKEKP FKTGRGRIST PERKVAKKEP 251 GDEEPFRSVG LPIGLPLSSM IPYTHFDVQF LEKFGVTFRR EGETVTLKCT
1451 STVSRDEVRR KKAVYKKAEL AKKTEVQAHS PSRKFILKPA IKYTRPTHLS 301 MLVTPDLKRV QPRAEWYRDD VLLKESKWTK MFFGEGQASL SFSHLHKDDE
1501 CVKRKTTAAG GESALAPSVF KQAKDKVSDG VTKSPEKRSS LPRPSSILPP 351 GLYTLRIVSR GGVSDHSAFL FVRDADPLVT GAPGAPMDLQ CHDANRDYVI
1551 RRGVSGDRDE NSFSLNSSIS SSARRTTRSE PIRRAGKSGT STPTTPGSTA 401 VTWKPPNTTT ESPVMGYFVD RCEVGTNNWV QCNDAPVKIC KYPVTGLFEG
1601 ITPGTPPSYS SRTPGTPGTP SYPRTPHTPG TPKSAILVPS EKKVAIIRTP 451 RSYIFRVRAV NSAGISRPSR VSDAVAALDP LDLRRLQAVH LEGEKEIAIY
1651 PKSPATPKQL RLINQPLPDL KNVKSKIGST DNIKYQPKGG QVQIVTKKID 501 QDDLEGDAQV PGPPTGVHAS EISRNYVVLS WEPPTPRGKD PLMYFIEKSV
1701 LSHVTSKCGS LKNIRHRPGG GRVKIESVKL DFKEKAQAKV GSLDNAHHVP 551 VGSGSWQRVN AQTAVRSPRY AVFDLMEGKS YVFRVLSANR HGLSEPSEIT
1751 GGGNVKIDSQ KLNFREHAKA RVDHGAEIIT QSPGRSSVAS PRRLSNVSSS 601 SPIQAQDVTV VPSAPGRVLA SRNTKTSVVV QWDRPKHEED LLGYYVDCCV
1801 GSINLLESPQ LATLAEDVTA ALAKQGL 651 AGTNLWEPCN HKPIGYNRFV VHGLTTGEQY IFRVKAVNAV GMSENSQESD
701 VIKVQAALTV PSHPYGITLL NCDGHSMTLG WKVPKFSGGS PILGYYLDKR
751 EVHHKNWHEV NSSPSKPTIL TVDGLTEGSL YEFKIAAVNL AGIGEPSDPS
ACTN3 Value matched=29 Protein sequence coverage=34% 801 EHFKCEAWTM PEPGPAYDLT FCEVRDTSLV MLWKAPVYSG SSPVSGYFVD
1 MMMVMQPEGL GAGEGRFAGG GGGGEYMEQE EDWDRDLLLD PAWEKQQRKT 851 FREEDAGEWI TVNQTTTANR YLKVSDLQQG KTYVFRVRAV NANGVGKPSD
51 FTAWCNSHLR KAGTQIENIE EDFRNGLKLM LLLEVISGER LPRPDKGKMR 901 TSEPVLVEAR PGTKEISAGV DEQGNIYLGF DCQEMTDASQ FTWCKSYEEI
101 FHKIANVNKA LDFIASKGVK LVSIGAEEIV DGNLKMTLGM IWTIILRFAI 951 SDDERFKIET VGDHSKLYLK NPDKEDLGTY SVSVSDTDGV SSSFVLDPEE
151 QDISVEETSA KEGLLLWCQR KTAPYRNVNV QNFHTSWKDG LALCALIHRH 1001 LERLMALSNE IKNPTIPLKS ELAYEIFDKG RVRFWLQAEH LSPDASYRFI
201 RPDLIDYAKL RKDDPIGNLN TAFEVAEKYL DIPKMLDAED IVNTPKPDEK 1051 INDREVSDSE IHRIKCDKAT GIIEMVMDRF SIENEGTYTV QIHDGKAKSQ
251 AIMTYVSCFY HAFAGAEQAE TAANRICKVL AVNQENEKLM EEYEKLASEL 1101 SSLVLIGDAF KTVLEEAEFQ RKEFLRKQGP HFAEYLHWDV TEECEVRLVC
301 LEWIRRTVPW LENRVGEPSM SAMQRKLEDF RDYRRLHKPP RIQEKCQLEI 1151 KVANTKKETV FKWLKDDVLY ETETLPNLER GICELLIPKL SKKDHGEYKA
351 NFNTLQTKLR LSHRPAFMPS EGKLVSDIAN AWRGLEQVEK GYEDWLLSEI 1201 TLKDDRGQDV SILEIAGKVY DDMILAMSRV CGKSASPLKV LCTPEGIRLQ
401 RRLQRLQHLA EKFRQKASLH EAWTRGKEEM LSQRDYDSAL LQEVRALLRR 1251 CFMKYFTDEM KVNWCHKDAK ISSSEHMRIG GSEEMAWLQI CEPTEKDKGK
451 HEAFESDLAA HQDRVEHIAA LAQELNELDY HEAASVNSRC QAICDQWDNL 1301 YTFEIFDGKD NHQRSLDLSG QAFDEAFAEF QQFKAAAFAE KNRGRLIGGL
501 GTLTQKRRDA LERMEKLLET IDRLQLEFAR RAAPFNNWLD GAVEDLQDVW 1351 PDVVTIMEGK TLNLTCTVFG NPDPEVIWFK NDQDIQLSEH FSVKVEQAKY
551 LVHSVEETQS LLTAHDQFKA TLPEADRERG AIMGIQGEIQ KICQTYGLRP 1401 VSMTIKGVTS EDSGKYSINI KNKYGGEKID VTVSVYKHGE KIPDMAPPQQ
601 CSTNPYITLS PQDINTKWDM VRKLVPSCDQ TLQEELARQQ VNERLRRQFA 1451 AKPKLIPASA SAAGQ
651 AQANAIGPWI QAKVEEVGRL AAGLAGSLEE QMAGLRQQEQ NIINYKTNID
701 RLEGDHQLLQ ESLVFDNKHT VYSMEHIRVG WEQLLTSIAR TINEVENQVL VMA5A Value matched=23 Protein sequence coverage=36%
751 TRDAKGLSQE QLNEFRASFN HFDRKQNGMM EPDDFRACLI SMGYDLGEVE 1 MVHFCGLLTL HREPVPLKSI SVSVNIYEFV AGVSATLNYE NEEKVPLEAF
801 FARIMTMVDP NAAGVVTFQA FIDFMTRETA ETDTTEQVVA SFKILAGDKN 51 FVFPMDEDSA VYSFEALVDG KKIVAELQDK MKARTNYEKA ISQGHQAFLL
851 YITPEELRRE LPAKQAEYCI RRMVPYKGSG APAGALDYVA FSSALYGESD 101 EGDSSSRDVF SCNVGNLQPG SKAAVTLKYV QELPLEADGA LRFVLPAVLN
901 L 151 PRYQFSGSSK DSCLNVKTPI VPVEDLPYTL SMVATIDSQH GIEKVQSNCP
201 LSPTEYLGED KTSAQVSLAA GHKFDRDVEL LIYYNEVHTP SVVLEMGMPN
251 MKPGHLMGDP SAMVSFYPNI PEDQPSNTCG EFIFLMDRSG SMQSPMSSQD
ARP3B Value matched=13 Protein sequence coverage=31% 301 TSQLRIQAAK ETLILLLKSL PIGCYFNIYG FGSSYEACFP ESVKYTQQTM
1 MAGSLPPCVV DCGTGYTKLG YAGNTEPQFI IPSCIAIRES AKVVDQAQRR 351 EEALGRVKLM QADLGGTEIL APLQNIYRGP SIPGHPLQLF VFTDGEVTDT
51 VLRGVDDLDF FIGDEAIDKP TYATKWPIRH GIIEDWDLME RFMEQVVFKY 401 FSVIKEVRIN RQKHRCFSFG IGEGTSTSLI KGIARASGGT SEFITGKDRM
101 LRAEPEDHYF LMTEPPLNTP ENREYLAEIM FESFNVPGLY IAVQAVLALA 451 QSKALRTLKR SLQPVVEDVS LSWHLPPGLS AKMLSPEQTV IFRGQRLISY
151 ASWTSRQVGE RTLTGIVIDS GDGVTHVIPV AEGYVIGSCI KHIPIAGRDI 501 AQLTGRMPAA ETTGEVCLKY TLQGKTFEDK VTFPLQPKPD VNLTIHRLAA
201 TYFIQQLLRE REVGIPPEQS LETAKAIKEK YCYICPDIVK EFAKYDVDPR 551 KSLLQTKDMG LRETPASDKK DALNLSLESG VISSFTAFIA INKELNKPVQ
251 KWIKQYTGIN AINQKKFVID VGYERFLGPE IFFHPEFANP DFMESISDVV 601 GPLAHRDVPR PILLGASAPL KIKCQSGFRK ALHSDRPPSA SQPRGELMCY
301 DEVIQNCPID VRRPLYKNVV LSGGSTMFRD FGRRLQRDLK RVVDARLRLS 651 KAKTFQMDDY SLCGLISHKD QHSPGFGENH LVQLIYHQNA NGSWDLNEDL
351 EELSGGRIKP KPVEVQVVTH HMQRYAVWFG GSMLASTPEF FQVCHTKKDY 701 AKILGMSLEE IMAAQPAELV DSSGWATILA VIWLHSNGKD LKCEWELLER
401 EEYGPSICRH NPVFGVMS 751 KAVAWMRAHA GSTMPSVVKA AITFLKSSVD PAIFAF
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SPTN1 Value matched=49 Protein sequence coverage=22% PLGA Value matched=9 Protein sequence coverage=54%
1 MDPSGVKVLE TAEDIQERRQ QVLDRYHRFK ELSTLRRQKL EDSYRFQFFQ 1 MEHKEVVLLL LLFLKSGQGE PLDDYVNAQG ASLFSVTKKQ LGAGSREECA
51 RDAEELEKWI QEKLQIASDE NYKDPTNLQG KLQKHQAFEA EVQANSGAIV 51 AKCEEDKEFT CRAFQYHSKE QQCVIMAENK KSSIIIRMRD VVLFEK
101 KLDETGNLMI SEGHFASETI RTRLMELHRQ WELLLEKMRE KGIKLLQAQK
151 LVQYLRECED VMDWINDKEA IVTSEELGQD LEHVEVLQKK FEEFQTDMAA SYNEMIN Value matched=27 Protein sequence coverage=20%
201 HEERVNEVNQ FAAKLIQEQH PEEELIKTKQ DEVNAAWQRL KGLALQRQGK 1 MLSWRLQTGP EKAELQELNA RLYDYVCRVR ELERENLLLE EELRGRRGRE
251 LFGAAEVQRF NRDVDETISW IKEKEQLMAS DDFGRDLASV QALLRKHEGL 51 GLWAEGQARC AEEARSLRQQ LDELSWATAL AEGERDALRR ELRELQRLDA
301 ERDLAALEDK VKALCAEADR LQQSHPLSAT QIQVKREELI TNWEQIRTLA 101 EERAARGRLD AELGAQQREL QEALGARAAL EALLGRLQAE RRGLDAAHER
351 AERHARLNDS YRLQRFLADF RDLTSWVTEM KALINADELA SDVAGAEALL 151 DVRELRARAA SLTMHFRARA TGPAAPPPRL REVHDSYALL VAESWRETVQ
401 DRHQEHKGEI DAHEDSFKSA DESGQALLAA GHYASDEVRE KLTVLSEERA 201 LYEDEVRELE EALRRGQESR LQAEEETRLC AQEAEALRRE ALGLEQLRAR
451 ALLELWELRR QQYEQCMDLQ LFYRDTEQVD NWMSKQEAFL LNEDLGDSLD 251 LEDALLRMRE EYGIQAEERQ RAIDCLEDEK ATLTLAMADW LRDYQDLLQV
501 SVEALLKKHE DFEKSLSAQE EKITALDEFA TKLIQNNHYA MEDVATRRDA 301 KTGLSLEVAT YRALLEGESN PEIVIWAEHV ENMPSEFRNK SYHYTDSLLQ
551 LLSRRNALHE RAMRRRAQLA DSFHLQQFFR DSDELKSWVN EKMKTATDEA 351 RENERNLFSR QKAPLASFNH SSALYSNLSG HRGSQTGTSI GGDARRGFLG
601 YKDPSNLQGK VQKHQAFEAE LSANQSRIDA LEKAGQKLID VNHYAKDEVA 401 SGYSSSATTQ QENSYGKAVS SQTNVRTFSP TYGLLRNTEA QVKTFPDRPK
651 ARMNEVISLW KKLLEATELK GIKLREANQQ QQFNRNVEDI ELWLYEVEGH 451 AGDTREVPVY IGEDSTIARE SYRDRRDKVA AGASESTRSN ERTVILGKKT
701 LASDDYGKDL TNVQNLQKKH ALLEADVAAH QDRIDGITIQ ARQFQDAGHF 501 EVKATREQER NRPETIRTKP EEKMFDSKEK ASEERNLRWE ELTKLDKEAR
751 DAENIKKKQE ALVARYEALK EPMVARKQKL ADSLRLQQLF RDVEDEETWI 551 QRESQQMKEK AKEKDSPKEK SVREREVPIS LEVSQDRRAE VSPKGLQTPV
801 REKEPIAAST NRGKDLIGVQ NLLKKHQALQ AEIAGHEPRI KAVTQKGNAM 601 KDAGGGTGRE AEARELRFRL GTSDATGSLQ GDSMTETVAE NIVTSILKQF
851 VEEGHFAAED VKAKLHELNQ KWEALKAKAS QRRQDLEDSL QAQQYFADAN 651 TQSPETEASA DSFPDTKVTY VDRKELPGER KTKTEIVVES KLTEDVDVSD
901 EAESWMREKE PIVGSTDYGK DEDSAEALLK KHEALMSDLS AYGSSIQALR 701 EAGLDYLLSK DIKEVGLKGK SAEQMIGDII NLGLKGREGR AKVVNVEIVE
951 EQAQSCRQQV APTDDETGKE LVLALYDYQE KSPREVTMKK GDILTLLNST 751 EPVSYVSGEK PEEFSVPFKV EEVEDVSPGP WGLVKEEEGY GESDVTFSVN
1001 NKDWWKVEVN DRQGFVPAAY VKKLDPAQSA SRENLLEEQG SIALRQEQID 801 QHRRTKQPQE NTTHVEEVTE AGDSEGEQSY FVSTPDEHPG GHDRDDGSVY
1051 NQTRITKEAG SVSLRMKQVE ELYHSLLELG EKRKGMLEKS CKKFMLFREA 851 GQIHIEEEST IRYSWQDEIV QGTRRRTQKD GAVGEKVVKP LDVPAPSLEG
1101 NELQQWINEK EAALTSEEVG ADLEQVEVLQ KKFDDFQKDL KANESRLKDI 901 DLGSTHWKEQ ARSGEFHAEP TVIEKEIKIP HEFHTSMKGI SSKEPRQQLV
1151 NKVAEDLESE GLMAEEVQAV QQQEVYGMMP RDETDSKTAS PWKSARLMVH 951 EVIGQLEETL PERMREELSA LTREGQGGPG SVSVDVKKVQ GAGGSSVTLV
1201 TVATFNSIKE LNERWRSLQQ LAEERSQLLG SAHEVQRFHR DADETKEWIE 1001 AEVNVSQTVD ADRLDLEELS KDEASEMEKA VESVVRESLS RQRSPAPGSP
1251 EKNQALNTDN YGHDLASVQA LQRKHEGFER DLAALGDKVN SLGETAERLI 1051 DEEGGAEAPA AGIRFRRWAT RELYIPSGES EVAGGASHSS GQRTPQGPVS
1301 QSHPESAEDL QEKCTELNQA WSSLGKRADQ RKAKLGDSHD LQRFLSDFRD 1101 ATVEVSSPTG FAQSQVLEDV SQAARHIKLG PSEVWRTERM SYEGPTAEVV
1351 LMSWINGIRG LVSSDELAKD VTGAEALLER HQEHRTEIDA RAGTFQAFEQ 1151 EVSAGGDLSQ AASPTGASRS VRHVTLGPGQ SPLSREVIFL GPAPACPEAW
1401 FGQQLLAHGH YASPEIKQKL DILDQERADL EKAWVQRRMM LDQCLELQLF 1201 GSPEPGPAES SADMDGSGRH STFGCRQFHA EKEIIFQGPI SAAGKVGDYF
1451 HRDCEQAENW MAAREAFLNT EDKGDSLDSV EALIKKHEDF DKAINVQEEK 1251 ATEESVGTQT SVRQLQLGPK EGFSGQIQFT APLSDKVELG VIGDSVHMEG
1501 IAALQAFADQ LIAAGHYAKG DISSRRNEVL DRWRRLKAQM IEKRSKLGES 1301 LPGSSTSIRH ISIGPQRHQT TQQIVYHGLV PQLGESGDSE STVHGEGSAD
1551 QTLQQFSRDV DEIEAWISEK LQTASDESYK DPTNIQSKHQ KHQAFEAELH 1351 VHQATHSHTS GRQTVMTEKS TFQSVVSESP QEDSAGDTSG AEMTSGVSRS
1601 ANADRIRGVI DMGNSLIERG ACAGSEDAVK ARLAALADQW QFLVQKSAEK 1401 FRHIRLGPTE TETSEHIAIR GPVSRTFVLA GSADSPELGK LADSSRTLRH
1651 SQKLKEANKQ QNFNTGIKDF DFWLSEVEAL LASEDYGKDL ASVNNLLKKH 1451 IAPGPKETSF TFQMDVSNVE AIRSRTQEAG ALGVSDRGSW RDADSRNDQA
1701 QLLEADISAH EDRLKDLNSQ ADSLMTSSAF DTSQVKDKRD TINGRFQKIK 1501 VGVSFKASAG EGDQAHREQG KEQAMFDKKV QLQRMVDQRS VISDEKKVAL
1751 SMAASRRAKL NESHRLHQFF RDMDDEESWI KEKKLLVGSE DYGRDLTGVQ 1551 LYLDNEEEEN DGHWF
1801 NLRKKHKRLE AELAAHEPAI QGVLDTGKKL SDDNTIGKEE IQQRLAQFVE
1851 HWKELKQLAA ARGQRLEESL EYQQFVANVE EEEAWINEKM TLVASEDYGD POSTN Value matched=21 Protein sequence coverage=32%
1901 TLAAIQGLLK KHEAFETDFT VHKDRVNDVC TNGQDLIKKN NHHEENISSK 1 MIPFLPMFSL LLLLIVNPIN ANNHYDKILA HSRIRGRDQG PNVCALQQIL
1951 MKGLNGKVSD LEKAAAQRKA KLDENSAFLQ FNWKADVVES WIGEKENSLK 51 GTKKKYFSTC KNWYKKSICG QKTTVLYECC PGYMRMEGMK GCPAVLPIDH
2001 TDDYGRDLSS VQTLLTKQET FDAGLQAFQQ EGIANITALK DQLLAAKHVQ 101 VYGTLGIVGA TTTQRYSDAS KLREEIEGKG SFTYFAPSNE AWDNLDSDIR
2051 SKAIEARHAS LMKRWSQLLA NSAARKKKLL EAQSHFRKVE DLFLTFAKKA 151 RGLESNVNVE LLNALHSHMI NKRMLTKDLK NGMIIPSMYN NLGLFINHYP
2101 SAFNSWFENA EEDLTDPVRC NSLEEIKALR EAHDAFRSSL SSAQADFNQL 201 NGVVTVNCAR IIHGNQIATN GVVHVIDRVL TQIGTSIQDF IEAEDDLSSF
2151 AELDRQIKSF RVASNPYTWF TMEALEETWR NLQKIIKERE LELQKEQRRQ 251 RAAAITSDIL EALGRDGHFT LFAPTNEAFE KLPRGVLERI MGDKVASEAL
2201 EENDKLRQEF AQHANAFHQW IQETRTYLLD GSCMVEESGT LESQLEATKR 301 MKYHILNTLQ CSESIMGGAV FETLEGNTIE IGCDGDSITV NGIKMVNKKD
2251 KHQEIRAMRS QLKKIEDLGA AMEEALILDN KYTEHSTVGL AQQWDQLDQL 351 IVTNNGVIHL IDQVLIPDSA KQVIELAGKQ QTTFTDLVAQ LGLASALRPD
2301 GMRMQHNLEQ QIQARNTTGV TEEALKEFSM MFKHFDKDKS GRLNHQEFKS 401 GEYTLLAPVN NAFSDDTLSM DQRLLKLILQ NHILKVKVGL NELYNGQILE
2351 CLRSLGYDLP MVEEGEPDPE FEAILDTVDP NRDGHVSLQE YMAFMISRET 451 TIGGKQLRVF VYRTAVCIEN SCMEKGSKQG RNGAIHIFRE IIKPAEKSLH
2401 ENVKSSEEIE SAFRALSSEG KPYVTKEELY QNLTREQADY CVSHMKPYVD 501 EKLKQDKRFS TFLSLLEAAD LKELLTQPGD WTLFVPTNDA FKGMTSEEKE
2451 GKGRELPTAF DYVEFTRSLF VN 551 ILIRDKNALQ NIILYHLTPG VFIGKGFEPG VTNILKTTQG SKIFLKEVND
601 TLLVNELKSK ESDIMTTNGV IHVVDKLLYP ADTPVGNDQL LEILNKLIKY
PLEXIN A4 Value matched=37 Protein sequence coverage=23% 651 IQIKFVRGST FKEIPVTVYT TKIITKVVEP KIKVIEGSLQ PIIKTEGPTL
1 MKAMPWNWTC LLSHLLMVGM GSSTLLTRQP APLSQKQRSF VTFRGEPAEG 701 TKVKIEGEPE FRLIKEGETI TEVIHGEPII KKYTKIIDGV PVEITEKETR
51 FNHLVVDERT GHIYLGAVNR IYKLSSDLKV LVTHETGPDE DNPKCYPPRI 751 EERIITGPEI KYTRISTGGG ETEETLKKLL QEEVTKVTKF IEGGDGHLFE
101 VQTCNEPLTT TNNVNKMLLI DYKENRLIAC GSLYQGICKL LRLEDLFKLG 801 DEEIKRLLQG DTPVRKLQAN KKVQGSRRRL REGRSQ
151 EPYHKKEHYL SGVNESGSVF GVIVSYSNLD DKLFIATAVD GKPEYFPTIS
201 SRKLTKNSEA DGMFAYVFHD EFVASMIKIP SDTFTIIPDF DIYYVYGFSS
251 GNFVYFLTLQ PEMVSPPGST TKEQVYTSKL VRLCKEDTAF NSYVEVPIGC HS35A Value matched=22 Protein sequence coverage=53%
301 ERSGVEYRLL QAAYLSKAGA VLGRTLGVHP DDDLLFTVFS KGQKRKMKSL 1 MAPPGPASAL STSAEPLSRS IFRKFLLMLC SLLTSLYVFY CLAERCQTLS
351 DESALCIFIL KQINDRIKER LQSCYRGEGT LDLAWLKVKD IPCSSALLTI 51 GPVVGLSGGG EEAGAPGGGV LAGGPRELAV WPAAAQRKRL LQLPQWRRRR
401 DDNFCGLDMN APLGVSDMVR GIPVFTEDRD RMTSVIAYVY KNHSLAFVGT 101 PPAPRDDGEE AAWEEESPGL SGGPGGSGAG STVAEAPPGT LALLLDEGSK
451 KSGKLKKIRV DGPRGNALQY ETVQVVDPGP VLRDMAFSKD HEQLYIMSER 151 QLPQAIIIGV KKGGTRALLE FLRVHPDVRA VGAEPHFFDR SYDKGLAWYR
501 QLTRVPVESC GQYQSCGECL GSGDPHCGWC VLHNTCTRKE RCERSKEPRR 201 DLMPRTLDGQ ITMEKTPSYF VTREAPARIS AMSKDTKLIV VVRDPVTRAI
551 FASEMKQCVR LTVHPNNISV SQYNVLLVLE TYNVPELSAG VNCTFEDLSE 251 SDYTQTLSKR PDIPTFESLT FKNRTAGLID TSWSAIQIGI YAKHLEHWLR
601 MDGLVVGNQI QCYSPAAKEV PRIITENGDH HVVQLQLKSK ETGMTFASTS 301 HFPIRQMLFV SGERLISDPA GELGRVQDFL GLKRIITDKH FYFNKTKGFP
651 FVFYNCSVHN SCLSCVESPY RCHWCKYRHV CTHDPKTCSF QEGRVKLPED 351 CLKKAEGSSR PHCLGKTKGR THPEIDREVV RRLREFYRPF NLKFYQMTGH
701 CPQLLRVDKI LVPVEVIKPI TLKAKNLPQP QSGQRGYECI LNIQGSEQRV 401 DFGWDG
751 PALRFNSSSV QCQNTSYSYE GMEINNLPVE LTVVWNGHFN IDNPAQNKVH
801 LYKCGAMRES CGLCLKADPD FACGWCQGPG QCTLRQHCPA QESQWLELSG
851 AKSKCTNPRI TEIIPVTGPR EGGTKVTIRG ENLGLEFRDI ASHVKVAGVE ERC2 Value matched=38 Protein sequence coverage=38%
901 CSPLVDGYIP AEQIVCEMGE AKPSQHAGFV EICVAVCRPE FMARSSQLYY 1 MYGSARTITN LEGSPSRSPR LPRSPRLGHR RTSSGGGGGT GKTLSMENIQ
951 FMTLTLSDLK PSRGPMSGGT QVTITGTNLN AGSNVVVMFG KQPCLFHRRS 51 SLNAAYATSG PMYLSDHEGV ASTTYPKGTM TLGRATNRAV YGGRVTAMGS
1001 PSYIVCNTTS SDEVLEMKVS VQVDRAKIHQ DLVFQYVEDP TIVRIEPEWS 101 SPNIASAGLS HTDVLSYTDQ HGGLTGSSHH HHHQVPSMLR QVRDSTMLDL
1051 IVSGNTPIAV WGTHLDLIQN PQIRAKHGGK EHINICEVLN ATEMTCQAPA 151 QAQLKELQRE NDLLRKELDI KDSKLGSSMN SIKTFWSPEL KKERVLRKEE
1101 LALGPDHQSD LTERPEEFGF ILDNVQSLLI LNKTNFTYYP NPVFEAFGPS 201 AARMSVLKEQ MRVSHEENQH LQLTIQALQD ELRTQRDLNH LLQQESGNRG
1151 GILELKPGTP IILKGKNLIP PVAGGNVKLN YTVLVGEKPC TVTVSDVQLL 251 AEHFTIELTE ENFRRLQAEH DRQAKELFLL RKTLEEMELR IETQKQTLNA
1201 CESPNLIGRH KVMARVGGME YSPGMVYIAP DSPLSLPAIV SIAVAGGLLI 301 RDESIKKLLE MLQSKGLPSK SLEDDNERTR RMAEAESQVS HLEVILDQKE
1251 IFIVAVLIAY KRKSRESDLT LKRLQMQMDN LESRVALECK EAFAELQTDI 351 KENIHLREEL HRRSQLQPEP AKTKALQTVI EMKDTKIASL ERNIRDLEDE
1301 HELTSDLDGA GIPFLDYRTY TMRVLFPGIE DHPVLRDLEV PGYRQERVEK 401 IQMLKANGVL NTEDREEEIK QIEVYKSHSK FMKTKIDQLK QELSKKESEL
1351 GLKLFAQLIN NKVFLLSFIR TLESQRSFSM RDRGNVASLI MTVLQSKLEY 451 LALQTKLETL SNQNSDCKQH IEVLKESLTA KEQRAAILQT EVDALRLRLE
1401 ATDVLKQLLA DLIDKNLESK NHPKLLLRRT ESVAEKMLTN WFTFLLYKFL 501 EKESFLNKKT KQLQDLTEEK GTLAGEIRDM KDMLEVKERK INVLQKKIEN
1451 KECAGEPLFS LFCAIKQQME KGPIDAITGE ARYSLSEDKL IRQQIDYKTL 551 LQEQLRDKDK QLTNLKDRVK SLQTDSSNTD TALATLEEAL SEKERIIERL
1501 VLSCVSPDNA NSPEVPVKIL NCDTITQVKE KILDAIFKNV PCSHRPKAAD 601 KEQRERDDRE RLEEIESFRK ENKDLKEKVN ALQAELTEKE SSLIDLKEHA
1551 MDLEWRQGSG ARMILQDEDI TTKIENDWKR LNTLAHYQVP DGSVVALVSK 651 SSLASAGLKR DSKLKSLEIA IEQKKEECSK LEAQLKKAHN IEDDSRMNPE
1601 QVTAYNAVNN STVSRTSASK YENMIRYTGS PDSLRSRTPM ITPDLESGVK 701 FADQIKQLDK EASYYRDECG KAQAEVDRLL EILKEVENEK NDKDKKIAEL
1651 MWHLVKNHEH GDQKEGDRGS KMVSEIYLTR LLATKGTLQK FVDDLFETIF 751 ESLTLRHMKD QNKKVANLKH NQQLEKKKNA QLLEEVRRRE DSMADNSQHL
1701 STAHRGSALP LAIKYMFDFL DEQADKHGIH DPHVRHTWKS NCLPLRFWVN 801 QIEELMNALE KTRQELDATK ARLASTQQSL AEKEAHLANL RIERRKQLEE
1751 MIKNPQFVFD IHKNSITDAC LSVVAQTFMD SCSTSEHRLG KDSPSNKLLY 851 ILEMKQEALL AAISEKDANI ALLELSASKK KKTQEEVMAL KREKDRLVHQ
1801 AKDIPSYKNW VERYYSDIGK MPAISDQDMN AYLAEQSRMH MNEFNTMSAL 901 LKQQTQNRMK LMADNYDDDH HHYHHHHHHH HHRSPGRSQH SNHRPSPDQD
1851 SEIFSYVGKY SEEILGPLDH DDQCGKQKLA YKLEQVITLM SLDS 951 DEEGIWA
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3.3 NG2/CSPG4 and cell migration 
 
3.3.1 NG2/CSPG4-Threonine phosphorylation pattern 
Post-translational modifications of NG2/CSPG4 provide an important means for regulating 
its interaction with extracellular and cytoplasmic binding partners. Phosphorylation and 
dephosphorylation have proved to be among the most versatile and functionally important 
types of post-translational modifications102. Two distinct threonine phosphorylation events 
PNRC2 Value matched=12 Protein sequence coverage=82%
1 MGGGERYNIP APQSRNVSKN QQQLNRQKTK EQNSQMKIVH KKKERGHGYN
51 SSAAAWQAMQ NGGKNKNFPN NQSWNSSLSG PRLLFKSQAN QNYAGAKFSE
101 PPSPSVLPKP PSHWVPVSFN PSDKEIMTFQ LKTLLKVQV
FSCN1 Value matched=27 Protein sequence coverage=46%
1 MTANGTAEAV QIQFGLINCG NKYLTAEAFG FKVNASASSL KKKQIWTLEQ
51 PPDEAGSAAV CLRSHLGRYL AADKDGNVTC EREVPGPDCR FLIVAHDDGR
101 WSLQSEAHRR YFGGTEDRLS CFAQTVSPAE KWSVHIAMHP QVNIYSVTRK
151 RYAHLSARPA DEIAVDRDVP WGVDSLITLA FQDQRYSVQT ADHRFLRHDG
201 RLVARPEPAT GYTLEFRSGK VAFRDCEGRY LAPSGPSGTL KAGKATKVGK
251 DELFALEQSC AQVVLQAANE RNVSTRQGMD LSANQDEETD QETFQLEIDR
301 DTKKCAFRTH TGKYWTLTAT GGVQSTASSK NASCYFDIEW RDRRITLRAS
351 NGKFVTSKKN GQLAASVETA GDSELFLMKL INRPIIVFRG EHGFIGCRKV
401 TGTLDANRSS YDVFQLEFND GAYNIKDSTG KYWTVGSDSA VTSSGDTPVD
451 FFFEFCDYNK VAIKVGGRYL KGDHAGVLKA SAETVDPASL WEY
LIMA1 Value matched=40 Protein sequence coverage=46%
1 MESSPFNRRQ WTSLSLRVTA KELSLVNKNK SSAIVEIFSK YQKAAEETNM
51 EKKRSNTENL SQHFRKGTLT VLKKKWENPG LGAESHTDSL RNSSTEIRHR
101 ADHPPAEVTS HAASGAKADQ EEQIHPRSRL RSPPEALVQG RYPHIKDGED
151 LKDHSTESKK MENCLGESRH EVEKSEISEN TDASGKIEKY NVPLNRLKMM
201 FEKGEPTQTK ILRAQSRSAS GRKISENSYS LDDLEIGPGQ LSSSTFDSEK
251 NESRRNLELP RLSETSIKDR MAKYQAAVSK QSSSTNYTNE LKASGGEIKI
301 HKMEQKENVP PGPEVCITHQ EGEKISANEN SLAVRSTPAE DDSRDSQVKS
351 EVQQPVHPKP LSPDSRASSL SESSPPKAMK KFQAPARETC VECQKTVYPM
401 ERLLANQQVF HISCFRCSYC NNKLSLGTYA SLHGRIYCKP HFNQLFKSKG
451 NYDEGFGHRP HKDLWASKNE NEEILERPAQ LANARETPHS PGVEDAPIAK
501 VGVLAASMEA KASSQQEKED KPAETKKLRI AWPPPTELGS SGSALEEGIK
551 MSKPKWPPED EISKPEVPED VDLDLKKLRR SSSLKERSRP FTVAASFQST
601 SVKSPKTVSP PIRKGWSMSE QSEESVGGRV AERKQVENAK ASKKNGNVGK
651 TTWQNKESKG ETGKRSKEGH SLEMENENLV ENGADSDEDD NSFLKQQSPQ
701 EPKSLNWSSF VDNTFAEEFT TQNQKSQDVE LWEGEVVKEL SVEEQIKRNR
751 YYDEDEDEE
STEAP3 Value matched=6 Protein sequence coverage=13%
1 MPEEMDKPLI SLHLVDSDSS LAKVPDEAPK VGILGSGDFA RSLATRLVGS
51 GFKVVVGSRN PKRTARLFPS AAQVTFQEEA VSSPEVIFVA VFREHYSSLC
101 SLSDQLAGKI LVDVSNPTEQ EHLQHRESNA EYLASLFPTC TVVKAFNVIS
151 AWTLQAGPRD GNRQVPICGD QPEAKRAVSE MALAMGFMPV DMGSLASAWE
201 VEAMPLRLLP AWKVPTLLAL GLFVCFYAYN FVRDVLQPYV QESQNKFFKL
251 PVSVVNTTLP CVAYVLLSLV YLPGVLAAAL QLRRGTKYQR FPDWLDHWLQ
301 HRKQIGLLSF FCAALHALYS FCLPLRRAHR YDLVNLAVKQ VLANKSHLWV
351 EEEVWRMEIY LSLGVLALGT LSLLAVTSLP SIANSLNWRE FSFVQSSLGF
401 VALVLSTLHT LTYGWTRAFE ESRYKFYLPP TFTLTLLVPC VVILAKALFL
451 LPCISRRLAR IRRGWEREST IKFTLPTDHA LAEKTSHV
ERLN1 Value matched=7 Protein sequence coverage=24%
1 MTQARVLVAA VVGLVAVLLY ASIHKIEEGH LAVYYRGGAL LTSPSGPGYH
51 IMLPFITTFR SVQTTLQTDE VKNVPCGTSG GVMIYIDRIE VVNMLAPYAV
101 FDIVRNYTAD YDKTLIFNKI HHELNQFCSA HTLQEVYIEL FDQIDENLKQ
151 ALQKDLNLMA PGLTIQAVRV TKPKIPEAIR RNFELMEAEK TKLLIAAQKQ
201 KVVEKEAETE RKKAVIEAEK IAQVAKIRFQ QKVMEKETEK RISEIEDAAF
251 LAREKAKADA EYYAAHKYAT SNKHKLTPEY LELKKYQAIA SNSKIYFGSN
301 IPNMFVDSSC ALKYSDIRTG RESSLPSKEA LEPSGENVIQ NKESTG
LEG9C Value matched=4 Protein sequence coverage=14%
1 MAFSGCQAPY LSPAVPFSGT IQGGLQDGFQ ITVNGAVLSC SGTRFAVDFQ
51 TGFSGNDIAF HFNPRFEDGG YVVCNTRQKG TWGPEERKMH MPFQKGMPFD
101 LCFLVQSSDF KVMVNGSLFV QYFHRVPFHR VDTISVNGSV QLSYISFQNP
151 RAVPVQPAFS TVPFSQPVCF PPRPRGRRQK PPSVRPANPA PITQTVIHTV
201 QSASGQMFSQ TPAIPPMMYP HPAYPMPFIT TIPGGLYPSK SIILSGTVLP
251 SAQRFHINLC SGSHIAFHMN PRFDENAVVR NTQINNSWGS EERSLPRKMP
301 FVRGQSFSVW ILCEAHCLKV AVDGQHVFEY YHRLRNLPTI NKLEVGGDIQ
351 LTHVQT
LEG9b Value matched=4 Protein sequence coverage=14%
1 MAFSGSQAPY LSPAVPFSGT IQGGLQDGFQ ITVNGAVLSS SGTRFAVDFQ
51 TGFSGNDIAF HFNPRFEDGG YVVCNTRQKG RWGPEERKMH MPFQKGMPFD
101 LCFLVQSSDF KVMVNGSLFV QYFHRVPFHR VDTISVNGSV QLSYISFQNP
151 RTVPVQPAFS TVPFSQPVCF PPRPRGRRQK PPSVRPANPA PITQTVIHTV
201 QSASGQMFSQ TPAIPPMMYP HPAYPMPFIT TIPGGLYPSK SIILSGTVLP
251 SAQRFHINLC SGSHIAFHMN PRFDENAVVR NTQINNSWGS EERSLPRKMP
301 FVRGQSFSVW ILCEAHCLKV AVDGQHVFEY YHRLRNLPTI NKLEVGGDIQ
351 LTHVQT
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within the cytoplasmic domain of the NG2/CSPG4 proteoglycan seem to regulate the 
cellular balance between proliferation and motility. Evidences show that protein kinaseC-α 
could mediate the phosphorylation of NG2/CSPG4 at Thr2256, resulting in enhanced cell 
motility. Extracellular signal–regulated kinase seems to phosphorylate NG2/CSPG4 at 
Thr2314, stimulating cell proliferation. The effects of NG2/CSPG4 phosphorylation on 
proliferation and motility should be dependent on β1-integrin activation51, but they need to 
be deeper investigated. To study NG2/CSPG4 phosporilation sites on sarcoma cells during 
cell migration, Western Blotting have been performed on NG2/CSPG4 expressed from 
immunosorted HT1080NG2+ cells. Three different protein expression patterns were obtained 
using different growth conditions, and referring to section 2.8 we could obtain the following 
protein cell lysate from HT1080NG2+ showed in figure 13: 
 Protein extract reflecting the proliferating expression pattern (P). 
 Protein expression pattern of cells during the migration (M). 
 Protein expression pattern during the starvation without any scratch (S). 
Two primary antibodies have been used: the antibody anti NG2/CSPG4 sc-33038 (santa cruz 
biotechnology, inc.) that reacts with all phosphorylated Threonines of NG2/CSPG4 of human 
origin; the Phospho-Threonine-X-Arginine Antibody #2351 (Cell Signaling Technology®), 
which detects endogenous levels of proteins containing the motive of NG2/CSPG4 belonging 
the Thr2256 we suppose is phosphorylated during cell migration. In all three the expression 
patterns investigated, NG2/CSPG4 was phosphorylated at different sites, while after 72 
hours of starvation and 48 hours of migration of HT1080NG2+ the protein resulted 
phosphorylated only at the site Thr2256 (Fig. 13, asterisk). 
 
Figure 13: Immunoblotting showing 
HT1080
NG2+ 
cells NG2/CSPG4 phosphorylation 
expression pattern. Left: the generic antibody 
anti-phosphorylated-NG2/CSPG4 has been 
employed, as control. It can be observed that 
in all the tested situation NG2/CSPG4 is 
phosphorylated. Right: the specific anti-
phosphorylated-Thr2256-NG2/CSPG4  has been 
employed. It reacts only with protein cell lysate 
obtained from HT1080
NG2+ 
after 72 hours of 
starvation and 48 hours of migration. 
Immunoblotting of actin with a polyclonal antiserum was used for normalization. Relative position of 
molecular weight marker is indicated to left.       
* 
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3.3.2 NG2/CSPG4  distribution during cell migration 
To verify the distribution of NG2/CSPG4 on cells during HT1080NG2+ and A375 cells 
migration, staining of NG2/CSPG4 with mAbs have been performed on migrating cells in 
wound healing assays (Figure 14). We observed that, in cells engaged in migration, 
NG2/CSPG4 expression advices how the protein localized on the migration front (red 
arrows, Fig. 14). 
 
 
Figure 14: NG2/CSPG4 distribution during HT1080
NG2+
 cells migration in wound healing assay, shown by 
immunofluorescence. Cells have been seeded on glass coverlisps in their complete growth medium. After the 
adhesion to the coverslips they were starved in serum-free medium for 24 hours, then a scratch has been done 
on the cell layer and cells were let migrate for 24 hours. Then paraformaldeide-fixed cells were incubated with 
anti-NG2/CSPG4 mAb 2161D7 and stained with AlexaFluo-594 (red) to detect NG2/CSPG4. Nuclei were 
counterstained with Hoechst (Blue). Arrows indicate the distribution of NG2/CSPG4. 
 
 
Slithering cells generate two major types of actin-based protrusive organelles, lamellipodia 
and filopodia, which have strikingly different actin polymerization machinery and are 
regulated by different signaling pathways198,199. It has been supposed that cofilin and fascin 
could be essential elements in the dynamic reorganization of the actin cytoskeleton28,200. As 
the transmembrane proteoglycan NG2/CSPG4 is able to interact with components of the 
extracellular matrix and with the actin cytoskeleton28, we investigated its localization durig 
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cell migrations compared with those of cofilin and fascin. Image 15 shows that NG2/CSPG4 
immune-colocalize with both these molecules, above all in cellular protrusions.  
 
 
 
 
 
Figure 15: Immunofluorescent co-localization of NG2/CSPG4 with fascin and cofilin. Distribution of NG2/CSPG4 
in A375 (A) and HT1080
NG2+
(B) filopodia and lamellopodia is shown: starved and migrating cells have been fixed 
in 4% paraformaldeide solution and then incubated with anti-fascin, anti-cofilin and/or anti-NG2/CSPG4 
antibodies as reported in the panels. Immunoreactions have been revealed as follows: A) Red AlexaFluor-594 
(Fascin and NG2/CSPG4 staining as indicated), Green AlexaFluor-488 (NG2/CSPG4 staining and cofilin staining 
as indicated), Hoechst (nuclei staining). B) Red AlexaFluor-594 (NG2/CSPG4 staining), Green AlexaFluor-488 
(Fascin and cofilin staining), Hoechst (nuclei counterstaining). 
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3.4 Functional diversity of NG2/CSPG4 variants 
 
3.4.1 Selection of anti-NG2/CSPG4 mAbs to induce cell apoptosis 
 
As reported in Table 1, many anti-NG2/CSPG4 antibody have been developed and tested on 
melanoma and mesothelioma, in which it has been seen to be able to block multiple 
signaling pathways important to cell growth, migration, and survival. As nothing was 
investigated in sarcoma tumors in this contest, we performed a preliminary experiment to 
compare the effect that antibodies producted in our laboratory have on melanoma and 
sarcoma cells.  With this aim, two mAbs and a negative control were tested on the following 
cells monolayer: A375 (Fig. 16A, left panel) and HT1080NG2+ (Fig. 16A, right panel) expressing 
NG2/CSPG4, and HT1080NG2- (Fig 16A, central panel) unexpressing NG2/CSPG4 . Figure 16A 
shows that mAbs 2172D6 and 2161F9 had no effect on HT1080NG2-, while seemed to detach 
A375 cells after 24 hours of treatment with the mAbs.  It is clear from figure 16A, panel on 
the right, that mAbs 2172D6 and 2161F9 caused the detachment of HT1080NG2+ cells. To 
better understand the nature of this detachment we first investigated if detached cells went 
through apoptosis when treated with anti-NG2/CSPG4 mAbs (Figue 16B). Late apoptotic 
melanoma and sarcoma cells have been detected with PI. Data are reported in histogram in 
figure 16B on the left: 2161D2, 2164H5 tripled apoptotic cells number, compared to the 
control, when dosed on A375 and HT1080NG2+ cells; 2166G4 had no effect on HT1080NG2+ 
while redoubled A375 apoptotic cells number. All the other tested mAbs, namely 2161F9, 
2161D3, 2172D6, 2172B12, 2164B6, caused late apotosis only on HT1080NG2+ cells. Early 
apotosis was detected in multiparamertic assays, that allowed to detect both the 
phosphatidylserine translocation that links to the annexin V, and the Mitochondrial 
Membrane Potential changes (Fig 16B, right). We can observe that 2161F9 had no effect on 
A375 while 2161D2 had a weak effect on A375. The clones 2161D3, 2172D6, 2172B12 had a 
moderate effect on A375 apoptosis, and 2164B6, 2164H5, 2166G4 wew responsible of the 
doubling of early apoptotic A375 cells. All mAbs were effective on HT1080NG2+, although 
mAb 2172B12 resulted to be the weakest among them. 
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               t0                  t1=6h              t2=24h                     t0                  t1=6h              t2=24h                t0                  t1=6h              t2=24h 
          A375     
               A375          HT1080NG-                                                    HT1080NG2+ 
  
 
Figure 16: Effect of anti-NG2/CSPG4 mAbs on cultured tumor cells. A) Cells were seeded and treated with anti-
NG2/CSPG4 mAbs 2171D6 and 2161F9 and a negative control. Pictures of the cell monolayer were taken at 
different times after the dosage (t0, t1=6h, t2=24h). Three cell lines have been tested: A375 (left) and 
HT1080
NG2+ 
(right) cells highly expressing NG2/CSPG4 , and HT1080
NG2 -
 (center) that do not express 
NG2/CSPG4. The two mAbs caused the detachment of cells after 24 hours of dosage on cells expressing 
NG2/CSPG4 , above all on HT1080
NG2+
. B) Apoptosis assays. On cells treated with anti-NG2/CSPG4 mAbs, late 
(left) and early (right) apoptosis have been detected with Acumen technology. For Late apoptosis propidium 
iodide (PI) has been used to stain cells. For early apoptosis, phosphatidylserine translocation is detected with 
AlexaFluor-488 Annexin V, while the Mitochondrial Membrane Potential changes are detected with 
MitoTracker Red. 
 
 
 
 
 
 
 
 
 
A 
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3.4.2 Effect of anti-NG2/CSPG4 antibodies on cell adhesion 
 
As with normal cells, the adhesion of tumor cells influences their cytoskeletal organization, 
activation of signal transduction pathways within the cell and nuclear events leading to 
changes in mRNA transcription and protein synthesis32. NG2/CSPG4 is linked to cell 
adhesion and, although its cytoplasmic domains has no intrinsic kinase activity, it may serve 
as binding sites for kinases and cytoskeletal proteins. It seems to influence cell adhesion, 
and frequently influence integrin receptor functions and signaling201. We investigated the 
effect that anti-NG2/CSPG4 mAbs have on HT1080N2+ sarcoma cell adhesion with the aim to 
select those able to determine the detachment of tumor cells from their substrate. This 
study was performed using the xCELLigence System (Roche) and data analysis were 
performed using the RTCA Software. The output of the system permits to display and record 
in real time the dynamic monitoring of cell attachment and spreading observed after mAbs 
dosage. Results are shown in plots (CI versus timing of the experiment), and histograms 
(displaying the CI slope): the first gives evidence of the attachment/spreading of cells, the 
latter refers to the slope of the curves reported in the plots. In these experiments each 
antibody was tested in quadruplicated, and two independent experiments were performed. 
From the results, we can observe that some tested antibodies had an effect on HT1080NG2+ 
vital functions, in fact their dosage on cells avoided their proliferation. This behavior of cells 
was not observed when positive control mediums were dosed on HT1080NG2+. The following 
mAbs had the described blocking activity: 2164H5, 2164B6, 2172B12, 2161D3. The most 
interesting effect was observed at the hands of mAb 2172D6, that determined the 
detachment of  HT1080NG2+ cells as shown in figure 17. 
 
 
68 
 
 
Figure 17: Anti-NG2/CSPG4 mAbs effect on sarcoma cells adhesion. Starved, adherent HT0180
NG2+
 cells were 
treated with mAbs and their adhesion was measured and monitored within 5 hours of treatment with the 
XcellIgence System (Roche).  A) Histograms show the effect of all mAbs on cell index (CI) variation within 5 
hours of dosage compared with the background (BKG= complete hybridoma growth medium containing an 
irrilevant IgG). B) Plot of the experiment shows the cell adhesion in real time within the 5 hours of mAbs 
dosage.  
 
 
 
3.4.3 Effect of anti-NG2/CSPG4 antibodies on cell migration 
 
Cell migration is a fundamental cellular process essential for tumor development and 
recurrence. Several studies suggest that NG2/CSPG4 plays a role in effective cell migration. 
We wanted to investigate if immunosorted cells from the same cell line differ in cell motility. 
From the wound healing assays performed on HT1080NG2+ and HT1080NG2- sarcoma cells, 
treated in the same conditions, we could observe that cells expressing NG2/CSPG4 migrate 
2164H5 
A 
B 
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faster closing the scratch, compared to the ones that do not express NG2/CSPG4. Analysis 
refers to 24 hours of monitoring (Fig. 18). 
 
Figure 18: Wound healing assay. 
Sarcoma cells immunosorted and 
selected to express NG2/CSPG4 
(HT1080
NG2+
, on the left) and to do 
not express NG2/CSPG4 (HT1080
NG2- 
on the right) are compared in a 
wound healing assay. Cells were 
seeded at 90% of confluence and 
starved in serum-free medium for 24 
hours. Their migration was measured 
and pictures were taken within 24 
hours of migration. HT1080
NG2+
 cells
 
covered the scratch while HT1080
NG2 -
 
cells did not. 
 
 
 
For the anti-NG2/CSPG4 mAbs screenings, HT1080NG2+ sarcoma cells have been employed 
and, on their cell monolayer, mAbs were dosed with the aim to select those able to block 
cell migration. Time lapse microscopy has been employed for the monitoring and measure 
of cells migration in an experimental time of 24 hours. The migration rate of cells is 
measured via the mean displacement (MD, i.e. the mean distance (μm) traveled per minute) 
of the cell centroid. The migratory potential of cell populations can then be expressed as the 
average mean displacement (AMD) of all cells in the analysis. In order to determine how the 
manual selection of the centroid positions of cells influences the calculated migration rates 
of individual cells and cell populations, we manually marked cells using a point-and-click 
system169. In this manual cell tracking method, we selected a subset of cells from each time-
lapse video for analysis, which is then assumed to represent the whole cell population. 
Green lines in figure 19A represent the tracking of cells when incubated with different 
mAbs. We can observe that the tracking was highly influenced by the kind of dosed mAb, 
and from the tracking analysis it is possible to identify which mAbs resulted more effective 
(Figure 19). In the first histogram (Fig. 19B) cells speed for each different well is plotted; in 
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the second histogram (Fig. 19C) the covered distances is plotted for each mAb dosed on 
HT1080NG2+ cells. We can identify some anti-NG2/CSPG4 mAbs able to interfere with normal 
vital cell functions when incubated with HT1080NG2+. In particular, the clones 2161F9, 
2164C3, 2164H5, 2172B12 slowed down cell migration in wound healing assay. It is 
interesting to observe that 2161D3 and 2172D6 determined a complete block of migration 
and the detachment of cells after few hours of dosage. 
 
Figure 19: Effect of anti-NG2/CSPG4 mAbs on cell migration in wound healing assays. Starved HT1080
NG2+
 cells 
were scratch in the middle of their monolayer and their migration was monitored by a time lapse microscope 
in 24 hours. A) tracking of cells (highlighted in green) when incubated with different mAbs. B) Histogram of cell 
speed obtained from the traking performed on migrating cells. C) Distance run from cells when incubated with 
the anti-NG2/CSPG4 mAbs. 
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4. DISCUSSION AND CONCLUSIONS 
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From the first studies on NG2/CSPG4 expression and function on melanoma cells1,35, till 
the last works on other kinds of tumors such as mesothelioma6,123 and breast carcinoma17, 
a large panel of anti-NG2/CSPG4 antibodies has been developed (Table 1). This large 
collection of anti-NG2/CSPG4 antibodies has facilitated the characterization of the 
antigenic profile of the molecule and has provided a useful probe to dissect the antigenic 
heterogeneity of tumor cells and tumor lesions, as well as to define the functional role of 
distinct domains of NG2/CSPG4. To approach the molecular traits of NG2/CSPG4 isoforms 
expressed by different cell lines we made use of a subset of our anti-NG2/CSPG4 mAbs 
found to recognize NG2/CSPG4 variants expressed in sarcoma (143B, HT1080NG+, SK-LMS-
1, SK-UT-1) and melanoma (A375, M2) cell lines, as well as proteolytic fragments of its 
ectodomain generated under both physiological and pathological conditions. Comparative 
immunoblotting experiments substantiated the presence of isoforms of the PG and a 
certain fragmentation. Data were confirmed when immunoblotting experiments were 
performed involving tissue extracts derived from regions of the fetal brain containing 
accumulations of NG2/CSPG4-expressing neovascular pericytes and the above reference 
tumour tissues/cells, lesions of glioblastoma multiform and by A375 melanoma cells. In 
these cases degree of proteolytic processing of the PG seemed significantly lower in fetal 
brain neovessels when compared to tumour tissues and isolated tumour cell lines. This 
findings may be unexpected considering that although tumors produce excessive amounts 
of metalloproteinases and other proteases capable of degrading NG2/CSPG4, such 
enzymes also accumulate in sprouting angiogenic vessels. Notably, angiogenic NG2/CSPG4 
isoforms of fetal brain appeared to be overall more glycosylated than their counterpart 
cancer-associated ones. The nature of this glycosylation and its biological significance 
remains to be defined. It remains similarly to be determined the precise molecular identity 
of the NG2/CSPG4 fragments generated by sprouting vessels and whether release of these 
fragments contributes to sequestering of extracellular signaling molecules (primarily 
growth factors), as reported for cell surface shedded syndecan fragments201,202.  
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To investigate eventual molecular interactors of NG2/CSPG4 expressed in melanoma 
cells, we performed a broad-spectrum analysis of A375 cells protein expression. MALDI-
TOF analyses lead to the identification of two types of interactors: one type seems to 
interact with NG2/CSPG4 strongly, since we could detect these molecules without the 
employment of cross-linking agent, the second panel of putative interactors seem to be 
linked to NG2/CSPG4 weakly, as their detection was possible only after a cross-linking 
treatment of cells before the protein pattern study. We do not know the nature of the 
interactions, neither if they are direct linked to NG2/CSPG4 or through other molecules, 
but this screening will give us a useful instrument for further more focused studies. 
Independently from the kind of links between NG2/CSPG4 and its putative interactors, 
we can do some speculation about them. First we are glad to confirm some of the 
molecules found to be NG2/CSPG4-interactors in previus studies and reported in figure 6 
such as: galectins, plasminogen-like protein (whose sequence in MASCOT data base could 
mimic those of plasminogen), and actins. Among the obtained results most of the 
proteins are involved in cell migration regulation and in the organization of 
cytosckeleton: Actin related protein, Microtubule-associated protein 2, Myosin-14, 
Myomesin-2, LIM domain and actin-binding protein, Plexin-A4, spectrin alpha chain, non-
erythrocytic 1 Protein. Among these molecules, we are particularly interested in a in-
deep analysis of the interaction between NG2/CSPG4 and Plexin A4, as it is a single-pass 
type I transmembrane protein176 found to promote tumors progression and tumors 
angiogenesis by enhancement of VEGF and bFGF signaling177. Moreover NG2/CSPG4 and 
plexin have been seen to be both involved together in injured central nervous systems203 
and from our experiments a similar cooperation could be hypothesized in melanoma 
cells. 
One of the most interesting results of this research has been the detection of fascin 
among the outcomes of the proteomic screening: in literature it has been observed that 
fascin- and NG2/CSPG4-positive structures are often localized to opposite poles of 
spreading cells, suggesting a possible role for the two classes of cellular extensions in the 
establishment of cell polarity during morphogenesis or migration28. Moreover from our 
immunocytochemical studies we could detect a co-localization of NG2 and fascin both in  
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sarcoma (H1080NG2+) and in melanoma (A375) cells as reported in section 3.3.2. Our 
observations are coherent with mass spectrometric results and could put the basis for a 
deeper investigation about NG2/CSPG4 and fascin relationship and their eventual 
interaction. 
Another interesting finding is represented by the putative association of NG2/CSPG4 
with the β5-integrin: in literature many studies revealed a relationship between 
NG2/CSPG4 and other kinds of integrins (α2-,α3- and α4-β1 integrins as reported in 
figure 6) but nothing has been proposed about the relation between this specific β5-
integrin and NG2/CSPG4. Nevertheless in a study performed on the role of β5-integrin, 
researchers injected A375 melanoma cell lines in mice lacking β5-integrins for the study 
of tumorigenesis and metastases processes, reporting that the absence of this integrin 
did not block vessel development, which was in fact enhanced, even if the angiogenesis 
decreased204. As β5-integrins usually block vessel formation, our findings of a putative 
interaction between NG2/CSPG4 and β5-integrins could explain its inhibition, possibly 
due to the interaction with NG2/CSPG4 . 
Concerning the detection, among the interactors, of erlin-1 (a single-pass type II 
membrane protein that has been found in associated with lipid raft-like domains of the 
cell membran195–197), periostin (that binds to heparin, induces cell attachment and 
spreading, plays a role in cell adhesion and may play a role in extracellular matrix 
mineralization found to be secreted in the extracellular space reaching the extracellular 
matrix183–185) and heparan sulfate glucosamine 3-O-sulfotransferase 3A1, we could 
hypothesize that NG2/CSPG4 could be involved in a pathway of endocytosis, maybe 
thanks to the involvement of TGF-β receptor through a clathrin-independent/lipid raft 
pathway, as it happens for many other proteoglycans205–209.  
We would be interested in the putative interaction between NG2/CSPG4 and the von 
Willebrand factor A domain-containing protein 5A (VMA5A), as this molecule has been 
found to play a role in tumorigenesis as a tumor suppressor, moreover researchers 
supposed that altered expression of this protein and disruption of the molecular pathway 
it is involved in, could contribute directly to modify tumorigenesis174. 
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PDZ domains are protein interaction modules that form sub-membranous complexes 
and regulate targeting and trafficking of cell surface molecules201. It has been 
demonstrated that the intracellular C-terminal domain of NG2/CSPG4 contains the 
binding motif QYWV, which can interact with PDZ domain-containing proteins49. This is 
compatible with one of the highest score putative interactors inferred with MALDI-TOF 
analysis, ERC protein 2, which interacts through its C-terminus with the PDZ domain PDZ-
containing proteins and it is found to be above all distributed in cell junction and 
associated to the cytoskeleton187. Like other PDZ-domain proteins found to interact with 
NG2/CSPG4 , also ERC protein 2 could play a scaffolding role in this interaction. 
It remains to be determined how NG2/CSPG4 would interact with the 
metalloreductase STEAP3, a six-pass membrane protein that localizes to vesicular-like 
structures at the plasma membrane. 
Finally, among the molecules discovered from the analysis, we noticed that, from all 
samples analyzed, 19 zinc-finger proteins and 5 coiled-coil domain-containing proteins 
have been identified: this let us think that NG2/CSPG4 could have high affinity for these 
kinds of domains probably along its cytoplasmic tail and even if the functional role of 
these interactions is unknown, we could speculate that they could have a structural 
significance. 
As outlined in Figure 6, NG2/CSPG4 has been demonstrated or hypothesized to 
interact with many extracellular and cytoplasmic molecules, with its cytoplasmic C-
terminal tail, the N-terminal extracellular domain, and the chondroitin sulphate chain it 
carries on the core protein. These interactions have been proposed to activate many 
signalling pathways such as the integrin/focal adhesion kinase signalling and MAPK 
pathway signaling, leading to tumor progression through a variety of cellular functions: 
cytoskeletal reorganization, migration, proliferation, invasion, survival and 
chemoresistance, epithelial–mesenchymal transition45,64,85,95,101 (Fig. 6B). Our findings 
confirm the involvement of NG2/CSPG4 in these molecular signaling pathways, and open 
the way for further investigations regarding the new putative molecular interactors 
found and their role in cancer. 
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The panel of anti-NG2/CSPG4 mAbs produced in our laboratory, when screened, 
showed reactivity towards NG2/CSPG4 expressed both on melanoma and sarcoma cells, 
opening the way to investigation also in sarcoma tumors. As in the literature there is no 
information in the contest of anti-NG2/CSPG4 target therapy on sarcoma tumors aimed 
at interfering with cell growth, migration, or survival, we screened in vitro our anti-
NG2/CSPG4 mAbs on sarcoma cells. Since from the first evidences, mAbs 2161F9 and 
2172D6 seemed to determine a detachment of cells when dosed on expressing-
NG2/CSPG4 sarcoma cells, and from further investigations, we could distinguish mAbs 
able to interfere with cell adhesion from those able to cause sarcoma cells apoptosis. 
These data confirm the involvement of NG2/CSPG4 in sarcoma and melanoma cell 
adhesion and survival, suggesting that some of the antibodies could be employed in in 
vivo tests to select those that could be employed in immunotherapy strategies, above all 
against sarcoma. In this contest we can group antibodies depending on their blocking 
activities: 1) pro-apoptotic mAbs on sarcoma cells (2161F9, 2164H5, 2161D2); 2) 
apoptosis inducing and adhesion blocking mAbs on sarcoma cells (2161D3, 2172D6, 
2172B12, 2164B6). We did not detect mAbs able to act only on the adhesion of cells 
without interfere with their survival. This effect could be due to the fact that the 
detached cells, revealed from the adhesion assays, could be all apoptotic cells,  and this 
suggests that selected mAbs are so aggressive against sarcoma to induce cell death in 24 
hours of dosage, while within 6 hours of administration in adhesion assays it is possible 
to detect also the effect on this function, even if the detachment is probably due to the 
pro-apoptotic action of mAbs on sarcoma cells. 
 
Cell adhesion is a complex mechanism involved in a variety of processes including cell 
migration and invasion32, and previously works showed that cells expressing the 
NG2/CSPG4 proteoglycan can attach, spread, and migrate on surfaces coated with anti-
NG2/CSPG4 mAbs, suggesting that engagement of NG2/CSPG4 can trigger the 
cytoskeletal rearrangements necessary for changes in cell morphology and motility26. For 
this reason we first aimed to confirmed the involvement of NG2/CSPG4 in cell migration 
with a wound healing experiment on HT1080NG2+ cells compared to HT1080NG2-. As we 
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expected, cells expressing NG2/CSPG4 migrated faster than their NG2/CSPG4-negative 
counterpart.  
Numerous structures are involved in regulating protrusion of membrane at the 
leading edge of motile cells199,  and there are evidences in literature that lamellipodia 
localize on the leading edges of migrating cells, while numerous filopodia are present on 
trailing edges28. To determine NG2/CSPG4 distribution in lamellopodia and filopodia, we 
coupled wound healing assays with immunocytochemical staining of NG2/CSPG4 mAbs 
together with fascin192 and cofilin210, since these molecules are typically expressed in 
membrane protrusions during cell migration28,199. Data show a co-immuno-localization of 
NG2/CSPG4 with both these molecules, suggesting a clear involvement of NG2/CSPG4 in 
migration of tumor cells and a probable function in cell membrane protrusion 
organization during cell migration. In the light of these results on migrating cells, 
screening of our anti-NG2/CSPG4 mAbs in wound healing assays have been performed to 
test their ability to interfere with sarcoma cells migration. These functional assays gave 
evident results of a blocking action, leading to the selection of a list of anti-NG2/CSPG4 
mAbs able to slow down sarcoma cells migration: 2161F9, 2164C3, 2172B12, 2164H5, 
2161D3, 2172D6 (weak effect). 
Comparing these results with the groups previously identified as functional blocking 
anti-NG2/CSPG4 mAbs, we can observe that 2161D3 and 2172B12 are the most 
aggressive antibodies since they interfere with all the cellular functions investigated. 
 
Our findings suggest NG2/CSPG4 as a promising new target to implement mAb-based 
immunotherapy of sarcoma, and we selected a panel of more aggressive antibodies able 
to inhibit tumor growth, adhesion and migration (mAbs 2161D3 and 2172B12), the 
interesting mAb 2164C3 which play a targeted action on block of sarcoma cell migration, 
and a panel of mAbs able to induce detachment of cells and finally their apoptosis: 
2161F9, 2164H5, 2161D2, 2161D3, 2172D6, 2172B12, 2164B6. These groups of mAbs 
need to be tested in vivo, with the possibility to set the experimentation of an anti-
NG2/CSPG4 drug against sarcoma, and a further molecular investigation to understand 
the nature of their different ability to block NG2/CSPG4 functions, that could be linked to 
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the different isoforms observed in our preliminary screening discussed above. Our 
findings of isoforms among the different cell lines would be in accordance with the in 
silico studies of the polymorphisms within the CSPG4 gene (Fig. 1) that show several 
missense SNPs coupled with 5 stop codon gains, which could lead to the expression of a 
NG2/CSPG4 molecule characterized by aminoacidic substitution, or even shorter forms 
expression of the protein. These observations and our findings let us hypothesize that 
NG2/CSPG4 isoforms we identified could be due to a different glycosylation pattern of 
the PG, to modification within the core-protein, and to shorter molecules expressed from 
different tumors in different contests. 
Our studies open the way for further studies aimed to the characterize these isoforms 
in the contest of the in vivo validation of anti-NG2/CSPG4 target therapy against different 
kinds of tumors. 
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